Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

AMOREPACIFIC

AMOREPACIFIC Group

Premium
Information Technology

AMOREPACIFIC Holdings is the pure holding company of Korea's oldest and largest pure-play beauty group. Through AMOREPACIFIC Corporation and its sister beauty subsidiaries (INNISFREE, ETUDE, espoir, AMOS PROFESSIONAL) and the OSULLOC tea business, it owns more than 30 brands across luxury skincare (Sulwhasoo, AMOREPACIFIC), masstige and digital-native skincare (LANEIGE, COSRX, INNISFREE), derma (AESTURA, ILLIYOON), makeup (HERA, ETUDE, espoir) and hair care (RYO, Mise-en-Scène, LABO-H). FY2025 consolidated revenue was KRW 4.62tn, up 8.5%, and operating profit was KRW 368.0bn, up 47.6%, the highest since 2019. The group is in the late stage of a "global rebalancing." It is cutting dependence on mainland China and Korean duty-free, and redeploying toward the Americas, EMEA, Japan and cross-border e-commerce (Amazon, Sephora, TikTok Shop). The equity trades at a deep holding-company discount (about 0.5x book). That discount reflects double-layer minority interests, family control and a subsidiary-driven earnings stream. --- ### Company's own description (paraphrased from the Q1 2026 quarterly report) The holding company classifies its consolidated operations into two segments, Cosmetics and Other. In Q1 2026 these accounted for about 95% and 5% of consolidated revenue respectively; in Q2 2026 the split was 96% / 4% [Src: Holdings Q1 2026 quarterly report, KIND, 15 May 2026; Butler.works segment data]. The company groups its sales routes into three channel buckets. In Q1 2026 their revenue shares were: - pure domestic Korea: 43% - duty-free and cross-border: 12% - overseas subsidiaries and exports: 45% [Src: Holdings and AP Corp Q1 2026 quarterly reports]. The operating subsidiary AMOREPACIFIC Corp. describes itself as researching, developing, manufacturing and selling cosmetics and beauty products worldwide. Its scope also includes medical beauty, beauty devices, inner beauty, hair/body/dental care, tea products, detergents and chemical compounds, packaging, facility management and equipment design [Src: StockHub company profile summarising DART descriptions]. The group's vision since September 2025 is "Create New Beauty", which aims at leadership in global beauty and wellness. It is executed through five priorities: Everyone Global, Holistic, Ageless, AMORE Spark and AI First [Src: AP Holdings FY2025 earnings release, 6 Feb 2026]. ### Business and revenue model (independent characterisation) | Dimension | Characterisation | |---|---| | Revenue model | Almost entirely product revenue: branded cosmetics, personal care, hair care and tea. There are no material subscription or licensing streams. Some service-like income exists, such as Jeju tea-museum F&B at OSULLOC (Matcha Station, Matcha Noodle Bar), but it is immaterial at group level [Src: Q2 2026 release] | | Holding-company income | At standalone level, Holdings earns dividends, brand royalties/fees and rental income from subsidiaries. Standalone revenue is not separately broken out in the sources reviewed (n/d) | | Value-chain position | Vertically integrated: in-house R&I (Yongin), owned manufacturing (Osan Amore Beauty Park and others), brand ownership, and a mix of owned retail, wholesale/distributor and DTC/e-commerce. Packaging and facilities were historically handled in-house through group affiliates | | Customer types | Mainly consumers. Trade customers include multi-brand shops (Olive Young domestically; Sephora, Ulta-type specialty, Boots internationally), department stores, duty-free operators, e-commerce platforms (Amazon, TikTok Shop, Qoo10, Coupang), distributors (e.g., Silicon2 for Europe) and salons (AMOS PROFESSIONAL) | | End-markets | Prestige and luxury skincare, masstige skincare, derma-cosmetics, colour cosmetics, hair care and styling, body and oral care, premium tea | | Earnings concentration | AMOREPACIFIC Corp. delivered KRW 4,252.8bn of revenue and KRW 335.8bn of OP in FY2025. That is 92% of group revenue and 91% of group OP (computed) [Src: FY2025 earnings release] | The structural fact that matters most for equity holders is the ownership chain. Holdings and related parties own about 50% of AMOREPACIFIC Corp. (50.14% at 31 Mar 2026) [Src: AP Corp Q1 2026 quarterly report]. Non-controlling interests therefore absorb most consolidated profit. In FY2025, profit attributable to owners of Holdings was KRW 124.0bn out of KRW 292.2bn of total net income, or 42% (computed) [Src: Valueline consolidated IS].

Revenue$3.3B
Employees55
Market Cap$1.3B
Founded1945
Seoul, South Korea

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Amogreentech

Amogreentech Co., Ltd.

Premium
Information Technology

Amogreentech is a Gimpo-based, KOSDAQ-listed advanced-materials and components maker within the AMO Group. It commercialises proprietary nano-materials technology in three main revenue engines. The first is nanocrystalline/amorphous "high-efficiency magnetic" cores and components for power conversion in EVs, stationary storage and chargers. In this niche the company describes itself, and is described by brokers, as one of three global producers alongside Proterial (formerly Hitachi Metals) and Germany's VAC; Tesla is the dominant customer. The second is LFP-based small-format backup energy storage systems (ESS) for telecom towers, wind-turbine pitch systems and battery-electric locomotives. The third is electrospun nanofiber membranes ("vents") for waterproofing smartphones and vehicles. Thermal-interface materials, AMB ceramic substrates and metallic catalytic converters are smaller lines. With revenue of KRW 130.6 bn (FY2025) and a high-single-digit operating margin, it is a small-cap, customer-concentrated, export-oriented supplier into electrification, AI-driven power demand and robotics. --- **Company's own description.** Per the company's IPO materials and its consistent investor messaging (2019 KOSDAQ IR deck; IPO press conference, March 2019), Amogreentech develops and manufactures key components for EV, 5G, ESS and next-generation IT applications using nano-materials. Its stated core capability is nano-magnetic alloy design, rapid-solidification manufacturing and nano-alloy powderisation. Applied in metals, plastics, fibres and ceramics, this capability yields parts that cut energy-conversion losses, dissipate heat or provide waterproof/breathable functions. At IPO, management described its ambition as becoming a globally competitive Korean core-materials company (NewDaily, 8 Mar 2019). **Independent characterisation.** In economic terms Amogreentech today runs two businesses with different models: 1. **Advanced Materials (첨단소재)** — about 53% of 2Q26 revenue (Butler, 2Q26 mix). This is a component/materials manufacturing business with in-house melt-spinning, powder and nanofiber processes. It consists of (a) high-efficiency magnetic materials (FY2025: KRW 49.4 bn), (b) nanomembrane vents (KRW 29.9 bn) and (c) thermal materials (KRW 5.0 bn). Products are designed-in ("spec'd-in") on customer platforms, which creates multi-year, platform-tied revenue streams. Per SK Securities (23 Apr 2026), about 65–70% of magnetic sales go to Tesla, and 60–70% of the Tesla volume is for ESS (Megapack) rather than vehicles. 2. **Energy & Environment (에너지/환경)** — about 42% of 2Q26 revenue. This is mainly a system-integration business. The company imports LFP cells from China, designs the BMS and pack, and delivers customised backup ESS. Its competitive edge is BMS/packaging and customer-specific engineering, not cell manufacturing (Daishin, 25 Mar 2024; Research Alum via Financial News, 8 May 2023). The segment also includes nascent AMB substrate and metallic-converter lines. **Revenue model.** Revenue is almost entirely product sales (components and finished ESS systems). No material service, subscription or licensing revenue was found in any source. ESS is project/lot-based and lumpy. Magnetic and membrane revenue is recurring volume tied to customer production schedules. **Value-chain position.** Tier-2/Tier-1 materials and components supplier. Magnetic cores go to OEMs (Tesla) and power-electronics makers (SMA Magnetics was named as an ESS-inductor customer in the 2019 IR deck). Membranes go to handset OEMs (Samsung Electronics). ESS goes to system OEMs and operators: KK Wind Solutions (wind control systems), Progress Rail (a Caterpillar subsidiary, locomotives), American Tower, KT and LG Uplus (telecom), and SoftBank and KDDI (Japanese telecom, from 2H26). **Customer types and end-markets.**

Revenue$0.1B
Employees346
Market CapN/A
Founded2004
Gimpo, South Korea
Amit

Amit International Limited

Premium
Information Technology

Amit International Limited is a Mumbai-based, BSE-listed micro-cap that began life in 1994 as a manufacturer and exporter of cotton sports socks, consolidating two family partnership firms of the Doshi family that had operated since 1988. Following a 1995 IPO to expand sock capacity at Silvassa, the company exported primarily to the USA and Western Europe, later shifting toward procuring hosiery from China. Competition from lower-cost producers in Pakistan and Bangladesh made manufacturing unviable, and the company ceased production; trading revenue dwindled to INR 0.74 crore in FY2015 and has been nil since FY2017. Today the company is effectively a dormant holding shell with roughly INR 20 crore of assets — principally loans, advances and unlisted investments — generating small amounts of interest-type other income. Its auditor has repeatedly qualified the accounts, including over an unprovided INR 2.32 crore doubtful advance and possible unregistered-NBFC status. Management states it is evaluating yarn spinning and dyeing projects, but no project has been announced. --- ### Company's own description The company's Directors' Report for FY2024-25 states that there was no change in the nature of business during the year and that the company's main object is manufacturing and exporting textile products. Its memorandum objects, as summarised by IIFL and other data providers, cover trading in textiles, fabrics, readymade garments, yarn, hosiery, cotton and blended socks, vests, underwear and other knitted fabrics; textiles made of silk, art-silk, rayon, staple and synthetic fibres, cotton, wool, flax, hemp and jute; diamonds; brass cable wiping; and the business of spinning, texturising, crimping and twisting fibres and yarn. The company's website "About us" page (as summarised by Screener.in) states that the company formerly procured goods from China and exported 100% of its sock production to the USA and Europe (Germany, France, the Netherlands and the UK), but that competition from Pakistan and Bangladesh rendered operations unviable, leading to a decision to stop production, and that the company is "looking for some projects in spinning and dying of yarn". ### Independent characterisation On an independent reading of the financial statements, Amit International is not an operating textile company in any economic sense. The evidence is unambiguous: - **Revenue from operations has been zero for ten consecutive fiscal years (FY2017–FY2026)**, and zero in each of the 13 quarters from June 2023 to June 2026 (Screener.in, BSE quarterly results). - The company's FY2023-24 Directors' Report explicitly states: "There is no Revenue from operations." The FY2024-25 report states the company carried out no export or import activity and had no foreign exchange earnings or outgo. - Third-party summaries of the FY2026 audit report (Multibagg AI, June 2026; FilingReader, June 2026) state that the company reported zero trading or manufacturing activity during recent audit periods and that management attributed its lack of RBI registration to a period of inactivity in which no new projects were undertaken. ### Business model and revenue model | Dimension | Current state (FY2026) | Historical state (FY1995–c.FY2014) | |---|---|---| | Revenue model | No operating revenue; income is "other income" (interest/financial income on loans, advances and investments) | Product sales — manufactured and later traded cotton sports socks and hosiery, plus intermittent trading in other goods | | Product vs service vs subscription vs licensing | 0% / 0% / 0% / 0% of operating revenue (nil operating revenue) | ~100% product | | Value chain position | None active | Manufacturer (Silvassa plant) then importer-trader/exporter | | Customer types | None active; borrowers/investees are counterparties on financial assets (identities largely undisclosed; one named counterparty is Topson/Topsun Iron Ore India Pvt. Ltd.) | Overseas importers/brands in USA, Germany, France, Netherlands, UK | | End-markets | None active | Export hosiery (sports socks) | ### Income composition (INR lakh, per Directors' Reports and results filings) | Metric | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---| | Revenue from operations (INR lakh) | 0 | 0 | 0 | 0 | | Total income incl. other income (INR lakh) | 29.48 | 39.37 | 42.42 | 8.26 | | Profit before tax (INR lakh) | 3.90 | 8.63 | 16.30 | -15.25 | | Profit after tax (INR lakh) | 3.18 | 6.68 | 12.57 | -15.25 | Sources: Directors' Report FY2023-24 (FY2023, FY2024); Directors' Report FY2024-25 (FY2025); FY2026 audited results as summarised by FilingReader and Multibagg AI (June 2026). FY2026 PBT is shown equal to PAT on the basis of Screener.in's 0% tax rate for FY2026; the company's PBT line for FY2026 was not directly sighted.

RevenueN/A
Employees2
Market CapN/A
Founded1994
Mumbai, India
Aminologics

Aminologics Co., Ltd.

Premium
Information Technology

### Key identifiers | Item | Detail | Source | |---|---|---| | Legal name | Aminologics Co., Ltd. ((주)아미노로직스) | [S1] | | Former name | A-Logics Co., Ltd. ((주)에이로직스), renamed Aminologics in September 2009 | [S1] | | Founding / incorporation date | 3 September 1997 | [S1] | | Incorporation jurisdiction | Republic of Korea | [S1] | | Headquarters | 3F Samoh Building, 151 Yeoksam-ro, Gangnam-gu, Seoul, Korea (Tel +82-2-761-4570) | [S1], [S5] | | R&D centre | 55 Osongsaengmyeong 5-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do (established 8 January 2010) | [S3] | | Exchange / ticker | KOSDAQ (Korea Exchange): 074430 | [S15] | | KOSDAQ registration | June 2004 | [S1], [S15] | | ISIN / CUSIP | — | — | | Fiscal year end | 31 December | [S13] | | Shares outstanding | 88.14 million (30 June 2026); 87.83 million from Q4 2015 through Q1 2026 | [S13] | | Employees | 40 (aggregator figure; reference date not stated) | [S15] | | Employee trend (3-year) | Not publicly disclosed in sources reviewed | — | | Auditor | — | — | | Representative directors (co-CEOs) | Oh Jang-seok and Oh Seong-seok | [S1], [S2] | | Largest shareholder | Samoh Pharm Co., Ltd. (삼오제약), 31.81% (end-2025) | [S6] | | Share price | KRW 977 (close, 15 October 2026) | [S13] | | Market capitalisation | ≈ KRW 86.1 bn (KRW 977 × 88.14 m shares; analyst calculation). Aggregators quoted KRW 88.9–89.5 bn on 14–15 October 2026 using slightly different share counts/prices | [S13], [S17] | | 52-week range | KRW 855 – KRW 1,940 | [S17] | | Business scope (as registered) | Manufacture of amino acids, amino acid derivatives and pharmaceutical intermediates; wholesale of active pharmaceutical ingredients | [S1] | Aminologics is a small Korean specialty-chemicals company that develops and sells non-natural (unnatural) and D-configured amino acids, protected amino acids (Fmoc, Boc, Cbz) and peptide-side-chain building blocks, built on a proprietary chiral-resolution platform it calls ARCA. A second, shrinking segment distributes six active pharmaceutical ingredients in Korea under domestic rights acquired from its parent, Samoh Pharm, in 2015. The company is asset-light: it owns no manufacturing plant and relies on contract manufacturing, principally Samoh's cGMP plant in Osong. Its strategic relevance has risen with global demand for GLP-1 peptide drugs, for which its catalogue now features semaglutide-, liraglutide- and tirzepatide-type side-chain intermediates. Its economic reality, however, is that of a captive technology-and-sales arm of the Samoh group: roughly 77% of 2025 revenue was booked through Samoh, which also controls the board and holds about 32% of the equity. --- ### What the company does Aminologics operates two reportable business lines: an Amino Acid business and an API (원료의약품, active pharmaceutical ingredient) business [S6], [S7], [S20]. **Amino Acid business.** After setting up a research institute in the second half of 2009, the company began researching, manufacturing and selling amino acids and amine-type compounds [S9]. It has since developed several dozen unnatural amino acids and D-amino acid derivatives, and has commercialised application materials such as protected amino acids, amino esters and oligopeptides [S9]. Named examples in its own descriptions include D-Serine, D-Phenylalanine and beta-Phenylalanine [S20]. The website catalogue lists 142 products across six families: amino acids and derivatives; Fmoc-protected amino acids; Boc-protected amino acids; Cbz-protected amino acids; Fmoc α-amino acids; and lipids and linkers [S4]. These materials are building blocks for peptide drugs, small-molecule APIs, agrochemicals and other fine chemicals [S14], [S8]. **API business.** In 2015 Aminologics acquired from its largest shareholder, Samoh Pharm, the domestic Korean business rights to six APIs for KRW 19.0 bn [S6]. It supplies these APIs — used in products for stroke, eye disease, dermatitis and cosmetics — to multiple Korean finished-dosage manufacturers [S20]. The specific API molecules are not named in the sources reviewed. ### Business model and revenue model | Dimension | Characterisation | Basis | |---|---|---| | Revenue type | ~100% product sales (amino acid materials and traded APIs); no disclosed service, subscription or licensing revenue | [S6], [S13] | | Manufacturing model | Outsourced: production through external contract manufacturers, starting in January 2017 with Samoh Pharm's Osong plant; the company has no production facility of its own | [S9], [S7] | | Sales channels | (1) indirect export via trading/distribution specialists including Samoh Pharm; (2) direct export to end buyers | [S6] | | Customer types | Global pharmaceutical companies and peptide manufacturers (amino acids); Korean finished-dose pharma companies (APIs) | [S8], [S20] | | End-markets | Peptide therapeutics (including GLP-1 class), small-molecule pharma intermediates, agrochemicals, sweeteners, cosmetics, research | [S8], [S14], [S5] | | Value-chain position | Upstream "raw material of the raw material": chiral building blocks sold to API/peptide manufacturers | [S11] | ### Company's own description The company describes itself (paraphrased from its CEO message) as having pursued, since 2009, the development of diverse biomaterials through chiral separation of amino acids based on its ARCA source technology, with the aim of commercialising amino acid technologies that drive both pharmaceutical and fine-chemical industries; it frames its unnatural-amino-acid work as a "first mover" role [S2]. A third-party English summary of its filings describes it as a specialty manufacturer of amino acids and derivatives whose core competency is the proprietary ARCA chiral-resolution platform, an enzymatic process enabling cost-effective production of high-purity chiral amino acids for pharmaceutical, fine-chemical, agrochemical and life-science uses [S14]. ### Independent characterisation Aminologics is best understood as a captive specialty-materials sales and development company within the Samoh Pharm group, not as a vertically integrated manufacturer. Three facts define it: 1. **Technology without plant.** The value proposition rests on process know-how (ARCA and downstream protection chemistry) and a catalogue of 140-plus SKUs, while physical production sits with Samoh's Osong cGMP plant and other CMOs [S7], [S4]. 2. **Extreme customer concentration through the parent.** Sales to Samoh were KRW 17.0 bn in FY2025, or 77.27% of revenue; about 96% of the Amino Acid segment's FY2025 sales of KRW 17.7 bn went to Samoh, which acts as a trading channel to end buyers [S6]. Revenue quality therefore depends on the opacity of Samoh's onward sales. 3. **Mix shift to peptide building blocks.** The Amino Acid segment rose from 37.4% of revenue in 2021 to 80% in FY2025 (KRW 17.7 bn of 22.0 bn) and 87% in Q2 2026 [S9], [S6], [S12]. The featured catalogue items — e.g., Fmoc-Lys(AEEAc-AEEAc-(γ-Glu-OtBu)-17-t-butoxycarboxyheptadecanoyl)-OH (CAS 1662688-20-1), tBuO-Ste-Glu(AEEA-AEEA-OSu)-OtBu (CAS 1118767-15-9), Fmoc-Lys(Pal-Glu-OtBu)-OH (CAS 1491158-62-3) and 20-(tert-butoxy)-20-oxoicosanoic acid (CAS 683239-16-9) [S4] — are, on structural analysis by this analyst, side-chain intermediates of the semaglutide, liraglutide and tirzepatide type. The company does not publicly name the drugs its materials serve; this mapping is the analyst's inference from chemical structure.

Revenue$0.0B
Employees40
Market CapN/A
Founded1997
Seoul, South Korea
AMINTANNERY

AMIN TANNERY LIMITED

Premium
Information Technology

Amin Tannery Limited is a nano-cap, promoter-controlled leather processor and footwear exporter belonging to the Kanpur-based Amin family's "Super House" leather ecosystem. Carved out of Super Tannery Limited in 2017 via a court-sanctioned demerger of its goat tannery business, the company tans and finishes goat leather and converts part of that leather into men's shoes, boots and shoe uppers at a single integrated facility in the UPSIDC Leather Technology Park at Banthar, Unnao. It is a Government-recognised Export House whose revenue (INR 34.80 Cr in FY2026) is earned principally from contract manufacturing to customer specifications rather than from owned consumer brands. Profitability is thin — net margins below 1% for every year since listing — and the balance sheet carries borrowings of roughly 2.2x equity alongside a very long working-capital cycle. The investment case therefore rests on export-demand recovery after the 2025–26 US tariff shock, operating leverage on an under-utilised plant, and group-level governance. --- ### Company's own description In its BSE filings and annual reports the company describes itself as a "manufacturer and exporter of finished leather and leather shoes" and as a Government-recognised Export House. The Screener.in summary, citing page 52 of the FY2025 annual report, characterises the principal activities as the manufacture and export of leather and leather shoes/uppers. Data vendors that parse the annual report (Musaffa, Simply Wall St) describe the product portfolio as two categories — finished leather, and leather shoes (including boots and shoe uppers) — with all manufacturing carried out at the Leather Technology Park, Banthar, Unnao. GuruFocus's description, drawn from the same filings, adds that the company processes leather "according to customer specifications", serving domestic and international markets. The FY2025 annual report (summarised by SustainabilityReports.com) also emphasises environmental compliance — dedicated water-treatment and chrome-recovery plants — and community support through the Amin Welfare Trust, which runs a hospital and a school. ### Independent characterisation Amin Tannery is best understood as a vertically integrated, made-to-order goat-leather tannery with a captive footwear-assembly line, operating at the small end of India's leather value chain. Its economics are those of a business-to-business converter: **Business model:** Raw goat skins (wet-blue or raw, sourced domestically) are tanned, retanned, dyed and finished into "finished leather", which is either sold to other footwear/leather-goods manufacturers and exporters or consumed internally to make shoe uppers and complete shoes/boots for overseas buyers. Orders are typically placed by foreign brands, importers or buying agents against specifications for leather article (thickness, finish, colour) or shoe style. **Revenue model:** Essentially 100% product revenue. There is no service, subscription or licensing income. Product codes on the company website (e.g., "AT FL 001" for leather articles, "SS-9170" for shoe styles) indicate a catalogue of sample articles used to solicit orders, rather than retail SKUs. **Value-chain position:** Midstream (tanning/finishing) with a partial step downstream into footwear manufacturing. It does not own retail distribution or a consumer brand of material scale; it sits upstream of global footwear brands and wholesalers. **Customer types:** Overseas footwear brands/importers and domestic footwear/leather-goods manufacturers (including; plausibly; other Kanpur exporters; related-party sales with group entities are a feature of this cluster). Named customers are not publicly disclosed. **End-markets:** Men's casual and work footwear and boots (export), and finished goat leather for footwear, gloves and leather goods. Industry data indicate that India's leather exports go more than 50% to the EU and about 22% to the US (Crisil, October 2025); Amin Tannery's own geographic split is not disclosed in retrievable sources.

Revenue$0.0B
Employees166
Market Cap$0.0B
Founded1946
Kanpur, India
Amicogen

Amicogen, Inc.

Premium
Information Technology

Bases: FY2024 is company IR (Q2 2024); FY2025 is PitchBook; FY2026 is THE VC (June 2026, pension-registry basis). Google Finance shows 236. Amicogen is a Jinju-based industrial biotechnology company. It was built on directed-evolution ("gene evolution") enzyme engineering. Its proprietary techniques, RCM™ point mutagenesis and RETT™ recombination, underpin pharmaceutical-grade special enzymes such as CX, SP and SC. These enzymes convert chemical antibiotic-intermediate processes (7-ACA, 7-ADCA) into greener enzymatic or fermentative routes. On that core it layered three further businesses: - enzyme-derived health-functional ingredients (NAG, PI/DCI, collagen peptides); - bioprocess consumables, namely chromatography resins via Puriogen and cell-culture media from a Songdo plant, positioned as Korea's only simultaneous domestic producer of both; - early-stage biopharma assets, including a non-PH20 human hyaluronidase. Between 2015 and 2024 most consolidated revenue came from Amicogen China's veterinary and human APIs. The 48.78% sale of Amicogen China in December 2024 shrank reported revenue by roughly three-quarters. The company is now a small, loss-making, governance-in-transition business. It depends on external capital to commercialise its media and resin capacity. --- ### Company's own description In its 2025 investor presentation, Amicogen describes itself as an industrial-biotech company. Its technology areas are gene evolution, biocatalysis and microbial metabolic engineering. Its main products are listed as pharmaceutical special enzymes (CX enzyme, SP and others) and bio-new-materials (N-acetylglucosamine, DCI/PI, collagen peptide, fucoxanthin and others). It frames its business in four pillars: Enzyme & Biopharma, Bio-Pharmaceutical Parts & Materials, Media & Resin, and Healthcare [S-IR25]. Its corporate tagline is "sustainable growth of humans and nature" [S-IR25]. ### Independent characterisation Amicogen is best understood as four businesses at very different maturity stages sharing one balance sheet: 1. **Enzymes & Green API (cash-generating core).** - CX enzyme is a biocatalyst for 7-ACA, the cephalosporin intermediate. Historically it was sold almost entirely to Chinese 7-ACA producers. - SP enzyme serves penicillin-class API synthesis. SC enzyme serves cephalosporin API synthesis. - "DX" strain/fermentation technology licences generate royalties. In 2020 DX technology was transferred to a Chinese partner producing over 1,000 t/yr of 7-ADCA. The company says this yields KRW 2–3bn of recurring royalties per year. CPC strain transfer was completed in 2023 [S-ASIA-DX]. 2. **Healthcare ingredients and finished products.** - NAG (joint and skin individually-recognised functional ingredient), PI/DCI, collagen peptide (CP) and collagen tripeptide (CTP), chitosan oligosaccharide, grain fermentation enzymes. - Sold B2B and through ODM to Korean pharma and food companies. - Sold B2C through the K-Nutra brand, launched December 2012 [S-KIRS]. 3. **Bioprocess consumables (growth bet, sub-scale).** - Chromatography resins (Protein A/G/L affinity; IEX S, Q, CM, DEAE; HIC; SEC) are made by Puriogen in Yeosu. - Cell-culture media (powder and liquid CHO media, custom media, CDO services) are made in Songdo. - Protein A ligands are produced at Jinju [S-IR25], [S-KIRS]. 4. **Pipeline / platform assets (pre-revenue).** - A novel skin-derived human hyaluronidase engineered for activity at neutral pH, aimed at IV-to-subcutaneous conversion of biologics. - Affinity ligands, including AAV-vector ligands. - Endolysin, with Germany's Lysando [S-IR25], [S-SUPPLE]. ### Business and revenue model **Product sales:** dominate: enzymes, ingredients, finished health foods, resins and media. **Licensing/royalty:** DX technology royalties and milestone-based consignment development fees. A February 2025 contract with a global antibiotic-API leader pays development milestones, then success and running royalties [S-ASIA-DX]. **Services:** media CDO (cell-line development, process development, media development) and custom media manufacturing [S-IR25]. **Subscription:** none. A precise product/licensing split is not publicly disclosed at consolidated level. Royalties were estimated at KRW 4–5bn for FY2023 [S-KIRS]. ### Value chain position and customers - Upstream supplier of biocatalysts and intermediates to antibiotic API makers, chiefly in China, with India targeted. - Upstream supplier of process consumables to biologics manufacturers and CDMOs. Samsung Bioepis's CEO attended the June 2024 plant opening, and the media national project counted Korean biologics makers ("C" and "S") as demand-side participants [S-MG24], [S-IR25]. - B2B ingredient supplier to health-food brands, for example FromBio's collagen launch in 2023 and Russia's Invita [S-KIRS], [S-DEAL7]. - B2C via K-Nutra, including exports to Kazakhstan [S-ASIA-COL]. ### End-markets Antibiotic APIs (human and, through the former subsidiary, veterinary), biologics and biosimilar manufacturing, nutraceuticals and inner-beauty, and cosmetics (endolysin-based skin microbiome products via partner Lysando).

RevenueN/A
Employees236
Market CapN/A
Founded2000
Jinju, South Korea
Amcorp

Amcorp Global Limited

Premium
Information Technology

Amcorp Global is a small, closely held property developer and investor. It is listed in Singapore and controlled by Malaysia's Amcorp Group Berhad, a diversified group with interests in banking, financial services, property and renewable energy. In FY2025 and FY2026 the company completed or exited the projects it inherited from TEE Land. These included the 70-unit freehold 35 Gilstead condominium, the Larmont Hotel in Sydney, Thai penthouses and the remaining Australian office units. The company is now a much smaller platform: about S$100m of assets, S$39.4m of cash, S$20.0m of secured borrowings and S$6.4m of FY2026 revenue. Its operating pipeline has three parts. The first is commercial shophouse phases in the SibuJaya township in Sarawak, developed jointly with a related Amcorp company. The second is a 50%-owned refurbishment of 126–134 Baker Street in London into 16 residential units. The third is a portfolio of minority-held strata commercial units in Singapore. Management describes its approach as value realisation, capital recycling and disciplined capital deployment [AR26]. --- **Company's own description.** The Annual Report 2026 describes Amcorp Global as an established property development company incorporated in Singapore. It says the company aims to create innovative and sustainable developments that meet client needs and has a number of projects locally and regionally [AR26, Corporate Profile]. The statutory description in [R26] Note 1 is narrower. The Company's principal activity is investment holding and providing corporate services to subsidiaries. The subsidiaries' principal activities are investment holding and real estate development. **What the company actually does.** The group has four revenue and value channels: 1. **Development for sale (main revenue line).** All FY2026 revenue of S$6.439m was "sales of properties" [R26 Note 5]. Of this, S$5.782m was recognised over time on development expenditures, which is the percentage-of-completion accounting applied to the SibuJaya commercial shophouse joint development. A further S$0.657m was recognised at a point in time from completed inventory, including Vietnam land and a Third Avenue retail unit. 2. **Rental income from completed and associate-held commercial assets.** This sits in "other operating income" rather than revenue. It was S$0.926m in FY2026 and S$0.933m in FY2025 [R26 Note 7]. Average occupancy of the Singapore commercial portfolio was 89% in FY2026 [AR26 Operations Review]. 3. **Equity-accounted interests.** These are associates holding strata commercial units in Singapore (TRIO, Hexacube, Flora Vista, 223 @ Mountbatten) and a 50% joint venture that owns 126–134 Baker Street, London. 4. **Capital recycling.** The company disposes of non-core completed assets: the Third Avenue office tower in Cyberjaya (pending), the Larmont Hotel and office units in Sydney (completed), Chewathai penthouses in Bangkok (completed) and New Zealand accommodation assets (2020). **Business and revenue model.** Revenue is 100% property sales. There is no subscription, licensing or service revenue. Hotel revenue (Larmont Hotel, Sydney) ended with the hotel's sale in FY2023. Revenue is lumpy and depends on the project cycle. Group revenue was S$84.5m in FY2023 and S$81.8m in FY2024 while 35 Gilstead was under construction, then fell to S$5.6m in FY2025 after that project reached 100% completion in May 2024 [R25]. **Value-chain position.** The company acts as developer and sponsor. It acquires or co-invests in land and buildings, obtains planning approvals, appoints main contractors (it has no in-house construction capacity), markets units through agents and manages leasing of retained commercial stock. Its Sarawak and London activity depends heavily on Amcorp Group entities. SibuJaya phases are joint developments with a related company that holds the township land bank. The Baker Street stake was bought from a fellow Amcorp subsidiary, Amcorp Prime Limited [R25 Note 17; R26 Note 11]. **Customers and end-markets.** Buyers are mainly retail property purchasers: Singapore residential buyers (35 Gilstead, Lattice One), Sarawak SME and commercial owner-occupiers or investors (SibuJaya shophouses), Singapore commercial tenants (F&B, retail, office occupiers in strata units) and, from 2027, prime central London residential buyers (Baker Street). No single customer reached 10% of revenue in FY2025 or FY2026 [R26 Note 4]. **Independent characterisation.** Amcorp Global is now best described as a sub-scale, sponsor-dependent holding vehicle. Its balance sheet is a mix of net cash, inventory held for sale and minority real-estate interests, and it has no self-sustaining development engine. FY2026 administrative expenses of S$3.27m equalled about 51% of revenue, and recurring rental income of about S$0.93m covers less than a third of overheads. Value creation depends on three things: (a) selling legacy inventory and minority stakes at or near book value, (b) delivering the SibuJaya phases at the margins recently achieved (35.3% group gross margin in FY2026), and (c) completing and selling the Baker Street units in 2027. The company has no CEO. Strategy is set by an all-non-executive board and a Group Executive Committee of four executives nominated by the majority shareholder [AR26 CG Report].

RevenueN/A
Employees14
Market CapN/A
Founded2012
Singapore
Ambika

Ambika Cotton Mills Limited

Premium
Information Technology

### Core identifiers | Field | Detail | |---|---| | Legal name | Ambika Cotton Mills Limited [S1] | | Former names | Ambika Cotton Mills Private Limited (incorporated 6 October 1988; converted to a public limited company on 5 September 1994) [S17] | | Founding / incorporation year | 1988 [S17] | | Incorporation jurisdiction | Tamil Nadu, India (Registrar of Companies, Coimbatore) | | Corporate Identity Number (CIN) | L17115TZ1988PLC002269 [S1] | | Registered office / headquarters | 15/9A, Valluvar Street, Sivanandha Colony, Coimbatore 641012, Tamil Nadu, India [S1] | | Telephone / email | +91 422 2491501 / 2491502; ambika@acmills.in [S10] | | Stock exchanges and tickers | NSE: AMBIKCO; BSE: 531978. Third-party profiles also list MSEI [S18] | | ISIN | INE540G01014 [S13] | | CUSIP | Not applicable (no US listing or ADR programme) | | Face value | ₹10 per equity share [S18] | | Shares outstanding | 5,725,000 equity shares (31 December 2025) [S13] | | Fiscal year end | 31 March [S14] | | Employees (latest) | 1,771 (third-party data aggregator) [S19] | | Employee trend (3 years) | Not publicly disclosed in sources retrieved | | Statutory auditor | S. Krishnamoorthy & Co., Chartered Accountants (per third-party company profile) [S18] | | Registrar and share transfer agent | SKDC Consultants Ltd, Coimbatore [S18] | | Company secretary and compliance officer | Radheshyam Padia [S18][S23] | | Chairman and Managing Director | P.V. Chandran (DIN 00628479) [S22] | | Market capitalisation (latest verified) | Approximately ₹916 cr at ₹1,600.45 per share (21 September 2026) [S24]. | | Short-term credit rating | Crisil A1+ (upgraded 28 July 2026) [S6] | | Website | http://www.acmills.in | Ambika Cotton Mills is a Coimbatore-headquartered, export-oriented manufacturer of premium 100% cotton compact yarn. It focuses on finer counts used by makers of premium branded shirts and T-shirts worldwide. The company runs four spinning units around Dindigul, Tamil Nadu. The long-standing base of 108,288 spindles was being lifted to 120,816 spindles during 2026 [S7][S20]. Captive wind and rooftop solar plants (27.4 MW and 8.33 MW respectively) cover much of its power needs [S9][S19]. Exports were 72.9% of turnover in FY2026 [S3]. Financially, Ambika is a small-cap, family-controlled company with a conservative, self-funded model. It was debt-free on 31 March 2026, held roughly ₹198 cr of free cash, and has paid a ₹35–37 dividend every year from FY2022 to FY2026 [S6][S3]. The investment case rests on niche quality positioning, a fortress balance sheet and cyclical earnings leverage to cotton spreads. Against that sit sub-scale revenue, commodity exposure and a margin profile well below the FY2022 cycle peak. --- ### What the company does Ambika Cotton Mills manufactures and sells cotton yarn, chiefly compact ring-spun combed yarn. Its by-products are cotton waste, and it also sells knitted fabric. It sells to garment and fabric manufacturers in India, Europe, Africa, North America and other parts of Asia [S19]. Third-party profiles drawn from the company's disclosures describe two product lines. The first is 100% cotton compact yarn in counts from 20s to 120s combed. The second is "Compact and Elitwist" yarn for hosiery (knitting) and weaving, with a concentration in the finer 60s–100s range for shirting [S20][S16]. The company blends imported cotton with Indian cotton to achieve consistent quality at fine counts [S16][S20]. It also operates a knitting facility that converts part of its yarn into fabric [S20]. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | Product sales, almost entirely manufactured goods (yarn, plus fabric and cotton waste). No subscription, licensing or service revenue | | Pricing | Spot and short-tenor contract pricing linked to global cotton and yarn markets. Margin is a function of the yarn–cotton "spread", conversion efficiency and power cost | | Value chain position | Upstream to midstream textiles: it buys raw cotton and supplies yarn to knitters and weavers, who feed garment makers serving apparel brands | | Customer types | Business-to-business: fabric and garment manufacturers making premium shirts and T-shirts [S19] | | End markets | Premium apparel (shirting and knitwear), export-led (72.9% of FY2026 turnover) [S3] | | Cost structure | Raw cotton is the dominant cost (cost of revenue ₹4,893 mn in FY2026, 62.7% of revenue) [S14]. Power cost is partly hedged through captive wind and solar [S9] | | Capital model | Capex funded entirely from internal accruals. The company was debt-free at the end of FY2026 [S5][S6] | ### Company's own description The FY2025 Directors' Report (37th Annual Report) describes raw cotton, the company's primary raw material, as an agricultural commodity subject to price and supply variability. It lists the sustainability and traceability certifications under which the company operates: the Better Cotton Platform, the U.S. Cotton Trust Protocol, OEKO-TEX (fabric, recycled polyester-cotton and yarn) and Cotton made in Africa. It describes the renewable infrastructure as 27.4 MW of wind and 8.33 MW of rooftop solar [S9]. Exchange profiles summarise the company as being engaged in manufacturing and selling speciality cotton yarn [S24]. ### Independent characterisation Ambika is best seen as a focused, quality-differentiated commodity converter. It does not have pricing power in the economic sense, because yarn prices are set by global supply and demand. Instead, it earns a persistent premium and above-peer margins through three things: **Count and quality mix:** It concentrates on fine-count compact yarn, where fewer mills compete and buyers pay for consistency. **Raw-material sourcing skill:** It blends imported fibres such as US and African cotton (the CMIA and USCTP memberships point to these origins) with Indian cotton. **Structural cost advantages:** Captive renewable power and the absence of interest-bearing debt help keep costs low. The model is deliberately unexciting. There are no acquisitions, no forward integration into garments and no leverage. That leaves earnings highly sensitive to the cotton cycle. FY2022 delivered a 19.5% net margin, while FY2024 delivered 7.6% [S14].

Revenue$0.1B
Employees1,771
Market CapN/A
Founded1988
Coimbatore, India
AMBANI

AMBANI ORGANICS LT

Premium
Information Technology

Ambani Orgochem is a four-decade-old, promoter-run Indian specialty-chemicals micro-cap. It is moving away from a commodity-adjacent base of water-based acrylic emulsions, binders, textile auxiliaries and metal-octoate paint driers. Its target is a "super-specialty" portfolio built on organic peroxides (polymerisation initiators and resin-curing agents) and salicylic acid with its salicylate esters (fragrance, UV-filter and pharmaceutical intermediates). Manufacturing sits at four units in MIDC Tarapur, Maharashtra, and a newer facility in Dahej, Gujarat. The Dahej plant was damaged by fire in February 2024 and restarted in February 2025. Revenue compounded at about 22–23% over five years, to ₹240.7 Cr in FY2026 and about ₹304 Cr on a trailing basis to September 2026. Profitability has lagged: EBITDA margins sit at 5–7% and net margins below 2%. The balance sheet is leveraged and working-capital heavy. The equity story now rests on Dahej ramp-up, product-mix upgrade, a capacity-led Tarapur expansion, and a pending ₹43.9 Cr preferential warrant raise. --- **Company's own description.** In filings and press releases the company calls itself a manufacturer, processor, importer, supplier and exporter of water-based specialty chemicals. It names the paper, paint, textile, carpet and adhesive industries as customers. The FY2025 MD&A and the November 2025 press release extend the list to organic peroxides, salicylic acid and salicylic derivatives. They add pharmaceuticals, fragrances, cosmetics and home care as end markets. The company stresses "green chemistry": water-based, APEO-free and low-VOC formulations. It holds ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 certifications, plus GOTS and ZDHC certification for selected textile chemicals (FY2025 MD&A). **Independent characterisation.** The company runs three economically distinct businesses under one reporting segment: 1. **Legacy water-based polymers and auxiliaries (Tarapur).** This covers acrylic and styrene-acrylic emulsions, PVA/PVP-type binders, thickeners, defoamers, dispersants, textile auxiliaries and detergent formulations. These are formulation-driven, moderately differentiated and price-competitive products. They sell to paint, paper, textile, carpet, construction and adhesive manufacturers. Raw-material pass-through (acrylic monomers, styrene, butyl acrylate) is high and margins are thin. The FY2026 investor presentation, as summarised by third parties, puts acrylic coatings and adhesives capacity at about 2,000 tonnes per month. It plans about 4,500 tonnes per month after a Tarapur expansion. 2. **Metal carboxylates / paint driers and FRP accelerators (Tarapur, partly through subsidiary Om Maruti Glasswool & Wirenetting Products).** Cobalt, manganese, lead, calcium, zinc, zirconium, iron, barium, cadmium, potassium and copper octoates and naphthenates, sold to paint, ink and FRP-composite makers. 3. **Peroxide and salicylate platform (Dahej, plus earlier peroxide production from 2019).** About 39 organic-peroxide grades sold under the "RAA PRO" brand, plus salicylic acid and 13 salicylate esters under the "AOPL" code. These are higher-value, hazard-intensive chemistries with fewer domestic producers. They serve polymer and composite makers, solar-encapsulant (EVA) producers, rubber vulcanisers, fragrance houses, personal-care formulators and pharma. **Business model and revenue model.** Revenue is essentially 100% product sales of manufactured chemicals, with some traded material. There is no subscription, licensing or service revenue. Sales are B2B, made to order or from stock, through direct sales across about 20 Indian states and exports to over 40 countries (FY2026 investor presentation, per third-party summary). Exports are material. Foreign-exchange earnings were ₹76.44 Cr in FY2025, about 40% of revenue from operations (FY2025 Directors' Report). **Value-chain position.** The company is a mid-stream converter. It buys petrochemical intermediates (acrylic monomers, styrene, tert-butanol/hydrogen peroxide derivatives, MEK, phenol/sodium phenolate for salicylic acid, metal salts, 2-ethylhexanoic acid) and sells functional ingredients that make up a small share of customers' bill of materials. It does not own feedstock. This leaves it exposed to raw-material volatility, mitigated only by price pass-through with a lag. **Customer types and end markets.** Paint and coatings (decorative and industrial), paper, textiles and carpets, adhesives and construction chemicals, composite FRP (boats, wind-turbine blades, tanks, marble slabs, sanitaryware), polymers and LDPE, rubber and tyres, solar-panel EVA encapsulants, fragrance and flavour, personal care (sunscreens, anti-ageing creams), home care (detergents, air care), and pharmaceuticals (pain balms, acne preparations). No customer is named publicly. Customer concentration is not publicly disclosed. Infomerics describes the clientele as diversified (rating rationale, 30 Mar 2023).

Revenue$0.0B
Employees124
Market CapN/A
Founded1985
Mumbai, India
Ambalal

Ambalal Sarabhai Enterprises Limited

Premium
Information Technology

Ambalal Sarabhai Enterprises is a small, family-controlled holding-and-operating company and one of India's oldest pharmaceutical names. Today it is a diversified micro-cap with consolidated revenue of about INR 202 crore (FY2026). It works almost entirely through subsidiaries and joint ventures across two reported segments. Pharmaceuticals (about 55% of FY2026 revenue) covers niche APIs such as Amphotericin B at Synbiotics, oncology and synthetic APIs at Asence Pharma, branded domestic formulations in oncology, fertility and women's health at Sarabhai Chemicals, effervescent and Vitamin C products, and international trading through Asence Inc. (USA). Electronics (about 45%) covers Systronics laboratory and analytical instruments and Telerad broadcast-equipment distribution. The company also holds a minority interest in the CoSara molecular-diagnostics JV with Nasdaq-listed Co-Diagnostics, which is exploring a US SPAC listing. ASE combines a legacy brand, a rebuilt balance sheet and several optionality-driven assets with thin operating margins, volatile earnings, low promoter ownership (31.35%) and no dividend. --- ### Company's own description In its latest Directors' Report (FY2025-26), management describes a strategy of operating through focused subsidiaries and joint ventures. It says this structure supports group operating efficiency, business development and long-term growth. The report says the group has 8 subsidiaries, 2 joint ventures and 1 associate. It highlights: **Asence Inc:** (wholly owned, USA): supplies finished dosage forms and APIs to international markets. It focuses on product registrations, partnerships and niche products for regulated and semi-regulated markets. **Asence Pharma Pvt. Ltd:** continued scaling up its oncology and synthetic API facility at Ranoli, Vadodara. It received the demerged Oncology and Pro-Fertility division of Sarabhai Chemicals. **Systronics (India) Ltd:** operates the Systronics division, which makes and markets analytical, laboratory and test-and-measurement instruments across India, and the Telerad division, which handles broadcast equipment. **Sarabhai Chemicals (India) Pvt. Ltd:** domestic branded pharmaceuticals in oncology, fertility, women's healthcare and other specialty therapies. - Group investments described as strengthening manufacturing capability, regulatory compliance and future growth. The company's exchange profile describes ASE as a pharmaceutical healthcare company that, through group companies, makes and markets pharmaceutical, molecular-diagnostic and electronics products in India and abroad (Screener, citing the annual report). Groww's company summary, drawn from company disclosures, adds two points. Vovantis, described as a JV, operates a USFDA-approved plant at Ranoli focused on US and European markets. Synbiotics is a USFDA-inspected maker of the antifungal API Amphotericin B. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Legal/operating structure | A listed parent with minimal standalone operations: standalone revenue of about INR 4 crore a year (Screener standalone), and standalone Q4 FY2026 revenue of INR 1.52 crore (Dion Global). Almost all revenue sits in subsidiaries. | | Revenue model mix | About 100% product sales across API, formulations, instruments and distributed broadcast equipment, plus small service/AMC income in electronics. No subscription or licensing revenue is disclosed. | | Pharma model | Mixed. API manufacture (B2B to formulators, India and export), contract/third-party manufacturing, branded generics sold to doctors and pharmacies in India, and trading/export through Asence Inc. | | Electronics model | Mixed. Own-manufactured analytical and lab instruments sold to labs, educational institutions, industry and government (Systronics), and a distribution/reseller model for broadcast and pro-AV equipment (Telerad). | | Value-chain position | Upstream in pharma (fermentation-derived and synthetic APIs). Mid-stream in formulations. Downstream marketing in domestic branded products. In electronics, the company acts as both an OEM and a distributor. | | Customer types | Pharmaceutical formulators and hospitals (API); doctors, pharmacies and hospitals (branded formulations); international distributors (Asence Inc.); educational and research labs, QC labs and government institutions (Systronics); broadcasters and production houses (Telerad). | | End-markets | Anti-infectives (antifungals), oncology, fertility/IVF, women's health, nutraceuticals (Vitamin C/effervescent), veterinary (per MarketInOut description), laboratory instrumentation, broadcast and pro-video, and molecular diagnostics through the CoSara JV. | ### Independent characterisation ASE is best understood as a legacy-brand micro-conglomerate in a multi-year rebuild. The founding family has spent roughly three decades settling legacy liabilities and building new vehicles. In an interview, Mohal Sarabhai described Asence as a deliberately fresh "springboard" company. The standalone entity still carries negative reserves: net worth was INR 59.48 crore against equity capital of INR 76.63 crore, with reserves of minus INR 17.15 crore (IIFL standalone balance sheet, March 2026). Value is concentrated in the subsidiaries and in equity-accounted stakes. The economic engine is modest. Consolidated revenue has moved within a INR 163–202 crore band since FY2021. Operating margins are mid-single-digit. FY2022 was the exception, when Amphotericin B demand during India's 2021 mucormycosis outbreak drove profit to INR 47 crore. Earnings are heavily influenced by other income and equity-accounted results. The equity story therefore rests mostly on optionality: the Ranoli oncology API plant ramp, regulated-market exports, the CoSara SPAC, and the electronics business's steady profitability.

Revenue$0.0B
Employees104
Market CapN/A
Founded1977
Ahmedabad, India
Amba

Amba Enterprises Limited

Premium
Information Technology

Amba Enterprises Limited is a Pune-based processor and trader of electrical steel. It converts cold-rolled grain-oriented (CRGO) and cold-rolled non-oriented (CRNO/CRNGO) silicon steel coils into slit coils, cut-to-length transformer laminations, toroidal cores, motor and generator stampings, and die-cast rotors. Its customers are transformer, motor, pump, UPS and appliance OEMs. It has described itself as one of India's largest transformer-core-lamination makers, with about 3,500 MT per year of capacity, and names CG Power, Siemens and Bharat Bijlee among its customers. Revenue rose from ₹111 Cr in FY2021 to ₹390 Cr in FY2026, a 29% CAGR, while operating margins stayed at about 3%. That margin profile is closer to a service-centre or trading model than a value-added manufacturer. The balance sheet is near debt-free with net cash of about ₹22 Cr, ROE is about 18%, and ROCE is about 22%. The equity trades at about 17x trailing earnings with no institutional ownership. The investment case rests on India's grid capex cycle against thin margins, scale disadvantages, and related-party supply dependence. --- ### Company's own description In its shareholder communication letter (filed on BSE; undated, revenue reference of about ₹220 Cr implies FY2022-23), Amba describes itself as follows: - One of India's largest manufacturers of transformer core lamination, with about 3,500 MT per year of manufacturing capacity. - A "multi-product, multi-location, multi-advantage group" serving recognised enterprises across India. - Specialised in silicon steel slit coils, cut-to-size transformer laminations, toroidal cores, motor stamping and die-cast rotors. - Serving the UPS, energy, distribution transformer, electrical, automobile, engineering and appliance industries. The company's long-standing descriptor in exchange filings and broker databases is "Power Engineering Solutions Company". It has manufactured and sold coil, transformer lamination sheet and related products since 1995 and diversified into lamination and stamping for rotating machines in 2014-15. ### What the company actually does (independent characterisation) | Value-chain stage | Players | Amba's role | |---|---|---| | Electrical steel production (CRGO/CRNO) | Global mills (CRGO largely imported into India; GTRI estimates domestic output meets less than one-tenth of demand); domestic CRNO producers | Buyer. CRNO coils are partly sourced from related party Shiv Shakti Enterprises. | | Service centre / processing | Slitters, cut-to-length processors, lamination and stamping shops | Core activity: slitting, cut-to-length, lamination cutting, stamping, die-casting | | Component | Transformer cores, motor stator/rotor stacks, die-cast rotors | Supplies laminations, cores and die-cast rotors | | Equipment OEM | Transformer, motor, pump, alternator, UPS makers (named customers: CG Power, Siemens, Bharat Bijlee) | Customer base | | End market | Utilities (T&D), industry, agriculture pumps, appliances, renewables | Indirect exposure | Amba sits in the middle of the electrical-steel value chain: **Business model indicators:** **Operating margin of about 3%:** (FY2022-FY2026 range 2.96%-4.2%) and inventory days of only 3 (FY2024-FY2026). This points to a back-to-back, order-driven model in which steel is bought against firm orders and passed through with a processing/trading spread. It is not a stock-and-sell or proprietary-product model. **Net fixed assets of only about ₹2-3 Cr:** against ₹390 Cr revenue (asset turnover on fixed assets above 100x). Either a large share of revenue is traded material, or processing assets are largely depreciated or leased. Aggregators note that the company also trades electrical steel and related raw materials. **Revenue model mix:** product sales (processed and traded steel products) account for essentially 100%. Job-work/processing services (slitting line, cut-to-length line) are offered, but their share is not publicly disclosed. There is no subscription or licensing revenue. **Geography:** predominantly domestic. GuruFocus states it serves domestic and export markets with the majority of revenue domestic. The export share is not publicly disclosed. ### Customer types and end-markets | End-market | Products supplied | Demand driver | |---|---|---| | Distribution & power transformers | CRGO slit coils, cut-to-length laminations, cores | Utility T&D capex, RDSS, renewables interconnection | | UPS / inverters / stabilisers | Toroidal cores, small laminations | Power-backup demand | | Electric motors (industrial) | CRNO stator/rotor stampings, die-cast rotors | Industrial capex, IE3/IE4 efficiency transition | | Pumps (domestic, agricultural, industrial) | Stampings, die-cast rotors, rotors with inserted shafts | Agriculture, housing, solar pumps | | Generators / alternators | Generator and alternator stampings | DG-set and alternator demand | | Automobile / engineering / appliances | Stampings, laminations | Auto, appliance cycles |

Revenue$0.0B
Employees15
Market CapN/A
Founded1992
Pune, India
Amara

Amara Raja Batteries Limited

Premium
Information Technology

**Auditor note.** - Deloitte Haskins & Sells LLP (FRN 117366W/W-100018) has been one of the joint auditors. - A second firm (FRN 003109S) was appointed at the 40th AGM (August 2025) for a five-year term ending at the 45th AGM. This appointment replaced Brahmayya & Co., whose tenure as joint auditor of the parent concluded. Amara Raja Energy & Mobility is India's second-largest lead-acid battery maker and the principal challenger to Exide Industries in a market the two companies effectively duopolise. Its Amaron brand, launched in 2000, built a reputation for maintenance-free reliability that won share in the automotive aftermarket and with Indian OEMs. On top of that franchise, it built a leading position in industrial VRLA batteries for telecom towers and UPS systems. It holds more than 60% combined share of telecom batteries across lead-acid and lithium chemistries (management, Q1 FY27 call). Since 2022 the company has been repositioning toward "new energy": - lithium-ion battery packs (already ~INR 809 crore of revenue in FY26); - a 16 GWh lithium-ion cell gigafactory programme in Telangana (~INR 9,500 crore), with the first 2 GWh due by June 2027; - a 10 GWh LFP-based battery energy storage system (BESS) facility. The investment case is about funding this pivot from a cash-generative, low-debt lead-acid business while lead-acid margins are under input-cost pressure. --- **What the company does.** Amara Raja designs, manufactures, sells and services energy-storage products. There are two reportable segments: 1. **Lead-acid batteries and allied products.** This covers: - automotive starter batteries for four-wheelers, two-wheelers and three-wheelers; - industrial batteries for telecom, UPS, power utilities and railways; - home energy products (inverter batteries, tubular batteries and home UPS); - allied products: lubricants (Amaron lubes), traded items, and plastic components, which have been in-house since the Mangal Industries carve-in. 2. **New energy business.** This covers: - lithium-ion battery packs for telecom, two/three-wheeler EVs and stationary storage; - EV chargers and power conversion products; - an upcoming lithium-ion cell gigafactory and BESS gigafactory, housed in wholly owned subsidiary Amara Raja Advanced Cell Technologies Pvt Ltd (ARACT). **Company's own description.** In its FY2026 results communication, the company describes itself as an energy storage and mobility solutions provider. It calls itself a leader in the low-voltage battery segment and says it is transitioning into a fully integrated new-energy business. Management lists the new-energy capabilities as spanning advanced cells, battery packs, chargers, power conversion technologies and energy storage systems (Vikramadithya Gourineni, Q1 FY27 release). **Business model.** - Almost entirely product-based manufacturing revenue. - There is no meaningful subscription or licensing income. - Service revenue is nascent. In Q1 FY27 the company piloted "Amaron Assist" in Hyderabad, an automotive services pilot (Q1 FY27 earnings call transcript). - Traded goods are material: management said trading revenue was about 15% of lead-acid battery revenue in Q1 FY27 (Q1 FY27 transcript). **Revenue model mix (Q1 FY27, consolidated revenue from operations INR 4,214.54 crore).** **Value-chain position.** Amara Raja is a vertically integrating battery OEM: **Upstream:** It recycles lead through a subsidiary, Amara Raja Circular Solutions Pvt Ltd (ARCSPL), and makes plastic containers and components in-house via the business acquired from group company Mangal Industries (NCLT-approved January 2024). **Midstream:** It manufactures cells and batteries. For lithium, it is moving from pack assembly to cell manufacturing. **Downstream:** It runs a nationwide aftermarket distribution network of franchisees, retailers and Amaron service points, and supplies OEMs and institutions directly. **Customer types.** - Automotive OEMs: passenger vehicles, two-wheelers and commercial vehicles. - Automotive aftermarket: replacement demand through distribution. - Telecom tower companies and operators. - UPS and data-centre integrators. - Power utilities, railways and industrial users. - Households: inverter and home UPS batteries. - EV makers: two/three-wheeler pack customers. - Export customers in 50+ countries (FY24 investor presentation), with the Middle East being 3–4% of revenue (CRISIL, March 2026). **End-markets served.** Automotive replacement and OEM; telecom infrastructure; IT/UPS/data centres; home backup power; solar and storage; electric mobility; grid and commercial & industrial storage (the BESS pipeline). **Independent characterisation.** Amara Raja is a mature, cash-generative Indian industrial franchise in an oligopolistic category. Its brand and distribution moats are strong in automotive replacement, which is the most profitable channel. Two structural tensions have reshaped the investment case since FY2024: 1. **Telecom lead-acid is in secular decline** as tower operators migrate to lithium. Amara Raja is cannibalising itself deliberately, keeping share by supplying lithium packs. 2. **The gigafactory programme requires several years of heavy capex.** Capex was INR 1,341 crore in FY26 against operating cash flow of INR 1,118 crore, and is guided at about INR 1,700 crore for FY27. This turned free cash flow negative in FY26 and is diluting consolidated margins before the new assets earn returns. The company is therefore best analysed as a "core plus option" structure: a steady lead-acid business (valued by brokers at roughly 15x earnings) plus a lithium/BESS option whose value depends on execution.

Revenue$1.6B
Employees8,000
Market CapN/A
Founded1985
Tirupati, India
EFC(I)

EFC (I) Limited

Premium
Information Technology

EFC (I) Limited is a Pune-headquartered, promoter-controlled Real Estate-as-a-Service platform that has transformed a dormant 1984-vintage textile-trading shell into one of India's fastest-growing listed flexible-workspace operators. The company leases (and increasingly owns) Grade-A commercial floor plates, fits them out, furnishes them from its own factory, and sub-leases them as fully serviced managed offices to more than 780 corporate clients. Its distinctive feature versus pure-play flex operators such as Awfis, Smartworks and IndiQube is vertical integration: a design-and-build (D&B) interiors business that also serves third parties, and an in-house furniture manufacturing unit, together generating roughly half of revenue. FY2026 revenue crossed ₹1,000 crore (INR 10,367 Mn, +58%) with PAT of INR 2,347 Mn. The model is capital-hungry and lease-heavy, funded through repeated equity issuance, and the stock has de-rated sharply (−43% over 52 weeks) despite strong reported earnings growth. --- ### Company's own description In its FY26 results release (29 May 2026) and Q1 FY27 release (29 July 2026), the company describes itself as "a leading real estate-as-a-service platform specializing in managed office solutions, interior design, and furniture manufacturing." It states that it was founded in 2014 by first-generation entrepreneur Umesh Kumar Sahay, is headquartered in Pune, and (as of Q1 FY27) operates 150 centres with 84,000+ seats across 25 cities, serving 780+ Indian and global corporates. The Ultrafresh acquisition release (13 August 2026) adds that the D&B vertical is supported by 85+ designers and engineers, has served 52+ reputed clients and has designed 5.91 million sq ft to date, while the furniture vertical operates from a three-acre manufacturing facility in Pune. ### Business model EFC operates three interlocking verticals: 1. **Managed Office Spaces ("Rental" segment).** EFC takes long-term leases on commercial buildings (or owns them through special-purpose subsidiaries), invests in fit-outs and furniture, and licenses seats/floors to enterprise clients on multi-year agreements. Revenue is recognised as rental/licence fees. Management cited average realisation of approximately ₹6,750–7,250 per seat per month (Q2 FY26 release). The company runs an OpCo–PropCo structure: an asset-light leased portfolio and an asset-heavy owned portfolio (e.g., Sprint Business Center, Wakadewadi, Pune). In July 2026 the board approved a demerger to move the asset-light leased business from subsidiary EFC Limited into the listed parent, leaving owned assets and associated borrowings in EFC Limited. 2. **Design & Build ("Interior" segment).** End-to-end interior fit-out and turnkey contracting, from concept through execution, for EFC's own centres and for third-party corporate and government clients (e.g., a Passport Seva Kendra general-works contract at Pashan, Pune). Revenue is project-based. Order book stood at over INR 2,280 Mn at Q1 FY27. 3. **Furniture Manufacturing ("Furniture" segment).** Office and modular furniture produced in-house (2,200+ SKUs; 75,000+ units delivered as of Q1 FY27) through subsidiary EK Design Industries Limited, which started operations in Pune in FY2025. The pending acquisition of Ultrafresh Modular Solutions adds modular kitchens and wardrobes and a factory at Nalagarh, Himachal Pradesh. A fourth line, EFC Retail Spaces, was launched in 2025 to lease premium showroom and shop space in metro and Tier-1 cities, with the first phase targeted for January 2026. Revenue from this line is not separately disclosed. ### Revenue model mix (FY2026, company segment data) | Revenue type | Segment | FY26 revenue (INR Mn) | Share of total | |---|---|---|---| | Recurring licence/rental (annuity-like) | Rental | 5,356.5 | 51.7% | | Project/contract services | Interior (D&B) | 4,377.9 | 42.2% | | Product sales | Furniture | 632.3 | 6.1% | | Subscription / licensing of IP | — | 0 | 0% | Source: EFC (I) Q4 & FY26 press release, 29 May 2026. ### Value-chain position EFC sits between landlords/developers and occupiers. It is (a) a tenant to landlords, (b) a landlord/licensor to occupiers, (c) a contractor for interiors, and (d) a manufacturer/supplier of furniture. Earlier descriptions of the group emphasise that its model treats landlords, interior fit-out contractors and vendors as stakeholders in a shared ecosystem. The vertical integration lets EFC capture fit-out and furniture margin that pure-play flex operators pay away to contractors. ### Customers and end-markets Customers are predominantly enterprises: Indian corporates, multinational GCCs (global capability centres), IT/ITeS firms, and government institutions (D&B). Client count rose from 600+ (Q2 FY26) to 750+ (Q4 FY26) to 780+ (Q1 FY27). Named marquee clients are not disclosed in sources reviewed. End-markets: Indian commercial office leasing (flex segment), corporate interior fit-out, institutional/modular furniture, and (nascent) retail leasing. ### Independent characterisation EFC is best understood as a levered, vertically integrated flex-office roll-up with three economically different businesses under one roof: a lease-arbitrage annuity business with high reported EBITDA (because Ind AS 116 moves rent below EBITDA into depreciation and interest), a working-capital-intensive contracting business, and a small but fast-growing manufacturing business. Reported profitability (FY26 PAT margin 22.6%) is unusually high versus listed peers, which merits scrutiny of related-party transactions, receivables quality (trade receivables rose to INR 4,055 Mn at FY26 from INR 1,516 Mn) and the treatment of owned assets. The company has relied on equity issuance (preferential issues in January 2024, a merger share issue in November 2025, a rights issue in May 2026 and a share-swap in October 2026) to fund growth.

Revenue$0.1B
Employees500
Market CapN/A
Founded1984
Pune, India
Amal

Amal Ltd

Premium
Information Technology

Amal Ltd is a small, debt-free maker of sulphur-based bulk chemicals controlled by Atul Ltd, one of India's largest integrated chemical companies. Its main job is backward integration for Atul. Its plants at Ankleshwar, Gujarat sit next to Atul's aromatics complex and have a combined 440 tonnes per day (TPD) of sulphuric-acid-equivalent capacity: 140 TPD in Amal itself and 300 TPD in its wholly owned subsidiary ASCL. They produce sulphuric acid, oleum, sulphur dioxide and sulphur trioxide, and sell by-product steam. About 38% of consolidated revenue comes from Atul. The rest goes to merchant customers in dyestuffs, pharmaceuticals, petrochemicals, textiles and personal care. Economics are driven almost entirely by the spread between product prices and the cost of sulphur, which is about 85% of costs. As a result, revenue swings with sulphur prices more than with volumes. Parent support, full capacity utilisation and a net-cash balance sheet make Amal a high-quality but structurally small, single-product, captive-anchored business. --- **What the company does.** Amal makes bulk chemicals by burning sulphur. Elemental sulphur is burned to make sulphur dioxide (SO2), which is converted catalytically to sulphur trioxide (SO3) and absorbed to give sulphuric acid (H2SO4, mainly 98%) and oleum (fuming sulphuric acid). Liquid SO2 and SO3 are also sold as downstream products in their own right. The process is strongly exothermic, so the plants recover heat as steam. Since June 2023 steam has been sold to Atul and is now a meaningful revenue line, at about 16% of FY2026 revenue according to CARE, which puts sulphur-based products at about 84%. **Company's own description.** Amal's annual reports (FY2015-16 through FY2025-26) describe the company as engaged in manufacturing and marketing bulk chemicals such as sulphuric acid and oleum and their downstream products such as sulphur dioxide and sulphur trioxide, with its plant at Ankleshwar, Gujarat. IIFL's summary of company disclosures adds that these chemicals are used in dyestuff, fertiliser, personal care, petrochemical, pharmaceutical and textile industries. **Business model and revenue model.** **Independent characterisation.** Amal is best understood as a captive utility for Atul that also sells into the merchant market. Atul built the ASCL facility to secure consistent, quality sulphuric acid supply, protect itself against volatile market prices and save freight (CARE). The arrangement gives Amal low sales risk and full utilisation, as CARE says it ran at full capacity in FY2025-FY2026. The trade-off is limited pricing power and exposure to sulphur price spikes that cannot be fully passed through. The steam business is a structural positive: it turns waste heat into revenue with almost no extra cost and ties Amal more closely into Atul's energy system. It also has no direct exposure to commodity-acid price cycles.

Revenue$0.0B
Employees81
Market CapN/A
Founded1974
Mumbai, India
Aluko

Aluko Co., Ltd.

Premium
Information Technology

Aluko is Korea's largest aluminium extruder and the listed core of the founder-controlled Aluko Group. The group is vertically integrated across billet casting (Alutec, Gogang Aluminium), extrusion die design and heat treatment (KPTU), precision extrusion and machining (Aluko and its Vietnam subsidiaries), and building design, curtain-wall installation and aluminium formwork rental (Hyundai Aluminium). The group presents this chain as a "one-stop" capability that no other domestic extruder offers. Founded in 1956, the business grew on the "Dongyang Aru-Sash" window brand. It moved into industrial applications after 2000: TV frames for Samsung, smartphone metal cases, railway car bodies, automotive parts, solar module frames and, from 2020, EV battery module cases for LG Energy Solution and SK On. Manufacturing now spans Daejeon, two Vietnamese production bases and, since 2025–26, two Tennessee plants. The company's current growth case depends on US-made solar frames for Hanwha Qcells. That case replaced an EV-battery thesis that weakened when a USD 600M BlueOval SK contract collapsed in early 2026. --- ### What the company does Aluko manufactures and sells aluminium extruded products and fabricated components. Through subsidiaries it also carries out building construction (windows and curtain walls) and rents aluminium formwork ("Al-Form") and real estate. Third-party descriptions match this: Stockopedia states that the company is mainly engaged in manufacturing and distributing aluminium extruded products and also rents aluminium forms and real estate. The company's 2024 and 2025 IR materials describe its value chain in five stages: 1. **Raw material and billet casting:** aluminium casting and alloy development (group affiliates Alutec and Gogang Aluminium). 2. **Die design and production:** extrusion die design, manufacture and heat treatment (affiliate KPTU). 3. **Extrusion and processing:** precision extrusion and machining of parts for industrial and building uses (Aluko, Hyundai Aluminium Vina, ALK Vina, Alu Materials America). 4. **Building design and installation:** design and construction, curtain-wall contracting, and Al-Form rental (Hyundai Aluminium, HDAL Vietnam). 5. **Automation:** the IR deck stresses "fully automated" cutting, pressing, inspection and packing lines. ### Company's own characterisation The June 2025 IR presentation describes the strategy along three axes: **Materials:** lightweighting and recycling. **Products:** a diversified portfolio. **Markets:** the United States and emerging industrial economies. The same deck lists the main product groups as: - EV battery module cases and pack housings (customers LGES and SK On) - Solar module frames, positioned as lightweight, durable clean-energy materials with rising exports to the Americas (Hanwha Qcells, Mission Solar) - Electronics: TV frames, appliance parts and heat-dissipation parts - Building materials: curtain walls and fire-rated windows - Mobile materials: high-gloss, premium-spec metal parts for Samsung Electronics - Ladders, linked to rising DIY demand ### Revenue model Revenue is overwhelmingly product sales of extruded and fabricated aluminium, priced off aluminium cost (LME-linked billet or scrap) plus a conversion margin. A meaningful construction-contract and rental stream comes from Hyundai Aluminium: curtain-wall projects recognised over time, plus Al-Form rental in Korea and Vietnam. The company has no subscription or licensing revenue. In the operating segments of the business report, the Q2 2026 revenue mix was Aluminium 68%, Construction & Rental 29%, Other 3% [Butler, citing DART half-year report]. ### Value-chain position and customers Aluko is a midstream semi-fabricator. It does not own bauxite, alumina or primary smelting. Korea has no primary aluminium smelting, so Korean processors import primary ingot and billet or remelt scrap [KIRS]. Aluko sells to three customer types: **Industrial OEMs and Tier-1 suppliers:** Samsung Electronics (TV and mobile), LG Display, Panasonic, Sony; Hyundai Mobis and Hyundai Motor (auto parts); Hyundai Rotem (railway, where Aluko is described as exclusive supplier of aluminium frames); LG Energy Solution and its affiliate LT Precision, and SK On (battery cases); Hanwha Qcells and Mission Solar Energy (solar frames) [KIRS; Aluko IR]. **Construction developers and contractors:** windows, curtain walls and formwork in Korea, Vietnam and Taiwan. Taiwan includes curtain-wall work on a new airport project [KIRS]. **Distributors and DIY/retail channels:** ladders and industrial profiles. ### End-markets The main end-markets are residential and commercial construction, consumer electronics (TV and mobile), EVs and batteries, solar PV, railway rolling stock, automotive lightweighting, shipbuilding (LNG carrier tank structures), and general industrial uses (pallets, profiles). In 1H 2024, standalone sales split about 84.1% domestic and 15.9% export [KIRS]. Consolidated revenue is more international because of the Vietnamese and US subsidiaries. ### Independent characterisation Analytically, Aluko is a low-margin, capital-intensive, cyclically exposed semi-fabricator. It has repeatedly reinvented its end-market mix: - construction (1970s–1990s) - LCD TV frames (2007–2013) - smartphone cases (2015) - EV battery cases (2020–2025) - US solar frames (2026–) Each wave produced a revenue step-up. None has yet delivered sustainably high returns. Consolidated operating margins stayed between 3% and 7% in FY2021–FY2025, and ROE stayed in single digits. The balance sheet is heavily weighted to short-term bank borrowings. The structural advantages are scale (the group describes its 8,000-ton press as the largest in Asia when installed in 1994), vertical integration, and long-standing qualification with Korean chaebol customers. The structural weaknesses are customer concentration, exposure to programmes whose timing the customer controls (as the BlueOval SK cancellation showed), thin margins, and group-level cross-guarantees.

Revenue$0.4B
Employees160
Market CapN/A
Founded1956
Daejeon, South Korea
Altron

Altron Limited

Premium
Information Technology

Headcount fell about 6% over two years. This reflects the ATM, Nexus and Altron Digital Business (ADB) cost-reduction actions, alongside the shift toward capital-light platform businesses. The FY24 figure comes from the FY24 Integrated Report. The FY25 and FY26 figures come from the FY26 Integrated Report as aggregated by Tracenable. Tracenable flags a possible basis inconsistency (period-end versus average). Altron is a 60-year-old South African technology group that has spent three years remaking itself from a sprawling IT-services and hardware conglomerate into a platform company. Since FY23 it has sold its ATM hardware unit to NCR, completed a management buyout of loss-making Altron Nexus (now Sentiv), turned around Altron Document Solutions, and concentrated capital on three annuity-rich platforms: Netstar (vehicle tracking, telematics and mobility data; 2.2 million subscribers), Altron FinTech (debit-order collections, payment switching and POS rentals) and Altron HealthTech (medical claims switching and practice management). In FY26 these Platforms produced 46% of revenue but 91% of EBITDA and 95% of operating profit. The group carries an ungeared balance sheet, earns a reported ROIC of about 23%, and has entered a self-described "Transformative Growth" phase. That phase is built on mobility, payments, digital identity and sovereign AI infrastructure (the NVIDIA-powered Altron AI Factory). It is exposed to a cyclical, subdued South African enterprise IT-services market through its IT Services "value engine". --- ### What the company does Altron organises its continuing businesses into three reporting segments plus a consolidation line (FY26 SENS): **Platforms:** Netstar, Altron FinTech, Altron HealthTech **IT Services:** Altron Digital Business (ADB), Altron Security, Altron Document Solutions (ADS) **Distribution:** Altron Arrow **Other:** consolidation and other international operations Management describes the group in its FY26 communications as a multi-platform business positioned to drive sustainable growth in South Africa's digital economy, underpinned by an ungeared balance sheet and an annuity-driven earnings base. The CMD materials frame the portfolio as a "Growth Engine" and a "Value Engine": **Growth Engine (Platforms):** an annuity revenue model with high visibility and low volatility, a capital-light architecture with near-zero marginal cost at scale, a unified data layer, and structurally higher ROIC. **Value Engine (IT Services, Distribution, Other):** lean, autonomous operations with a blue-chip customer base. Its role is to enable the platform ecosystem, provide early-mover exposure to AI through the AI Factory, and supply a digital-identity structural underpin. ### Business model and revenue model | Revenue characteristic | FY25 | FY26 | Source | |---|---|---|---| | Group annuity revenue as % of continuing revenue | 63% | 67% | FY26 SENS | | Platforms annuity revenue % | 89% | 91% | FY26 SENS | | Netstar annuity % | 91% | 92% | FY26 results presentation | | Altron FinTech annuity % | 84%–85% | 88% | FY26 SENS / CMD (FY25 shown as 84% in SENS and 85% in CMD table) | | Altron HealthTech annuity % | 93% | 96% | CMD pre-reading | | Altron Security annuity % | 79% | 83% | CMD pre-reading | | ADB annuity % | n/d | 51% | FY26 results presentation | | ADS annuity % | n/d | 43% | FY26 results presentation | | Altron Arrow annuity % | n/d | 0% | FY26 results presentation | The revenue model therefore spans four types: 1. **Subscriptions and rentals:** Netstar tracking subscriptions on capital rental devices, and FinTech POS device rentals. 2. **Transaction and processing fees:** FinTech debit-order and switching fees, and HealthTech claims-switching fees. 3. **Licences:** HealthTech practice and corporate licences, and Security PKI/digital-signing platforms. 4. **Project, product and resale revenue:** ADB systems integration and professional services, Security software resale, ADS hardware, and Arrow component distribution. Annuity revenue for the five months to 31 July 2026 rose further to 68% of group revenue (31 August 2026 operational update). ### Value-chain position and customers **Netstar:** owns the device-to-data chain. It covers hardware and installation, recovery and monitoring, tracking and fleet SaaS, fleet intelligence and mobility data-as-a-service. Customers include consumers, enterprise fleets, insurers (as an "insurance enabler") and vehicle OEMs (embedded telematics; international revenue includes Toyota). (CMD pre-reading; FY26 presentation) **Altron FinTech:** provides payment and collection infrastructure that, per the CMD, is embedded in every tier-1 South African bank. It serves micro-finance enterprises and SMEs (collections, credit management), banks and government (card personalisation and issuance), and retail and informal-sector merchants (integrated transaction solutions). (CMD pre-reading) **Altron HealthTech:** sits between private medical practices, hospitals and medical schemes. It switches about 107m healthcare transactions a year, worth R121bn in claims value. (CMD pre-reading) **Altron Security:** operates a WebTrust-certified trust centre, providing PKI, certificate services, digital signing and identity solutions to enterprises and public-sector identity programmes. (CMD presentation) **ADB and ADS:** are enterprise IT-services and managed document-services providers to large corporates and the public sector. Altron states it serves half of the JSE top-100 companies, including Vodacom, Capitec, Standard Bank and Implats (Daily Investor, February 2026). **Altron Arrow:** is a franchised electronic-component distributor in South Africa. Its FY25 market share gain of 4% is cited from Arei data (FY25 SENS). ### End-markets Mobility and insurance (Netstar); SME, micro-lending and retail payments (FinTech); private healthcare (HealthTech); national digital identity and enterprise trust services (Security); enterprise and government IT (ADB, ADS); and electronics manufacturing (Arrow). About 88% of group revenue is generated in South Africa (Edison, June 2026), down from 89% in FY24 (Edison, February 2025). ### Independent characterisation Altron is best understood as a South African platform holding company with an attached IT-services cash cow and turnaround book. Value is concentrated in two assets: Netstar (FY26 EBITDA R1,083m) and Altron FinTech (FY26 EBITDA R597m). Together they made up about 84% of group EBITDA. The IT Services segment contributes about half of revenue but only about 16% of operating profit, and its margin structure (4.1% operating margin in FY26) is structurally inferior. The investment debate therefore centres on three questions: the durability of platform growth and margins, management's willingness to keep or separate the lower-quality IT-services businesses, and capital allocation (organic reinvestment, special dividends, and as-yet-unexecuted platform M&A).

Revenue$0.5B
Employees4,334
Market CapN/A
Founded1965
Woodmead, South Africa
AltonSports

Alton Sports Co., Ltd.

Premium
Information Technology

Alton Co., Ltd. is South Korea's second-largest domestic bicycle brand owner and, by its own description, the country's leading electric-bicycle company. Founded in 1994 as an import/trading house, it evolved into a vertically integrated manufacturer with production in China (Tianjin) and Korea (Yangju), and pioneered commercial e-bikes in Korea from 2009–2012. Since March 2015 it has been controlled by INNOX Corporation, an IT-materials holding group. Alton sells general and electric bicycles under the alton, E-alton, INFIZA, ROADMASTER, Corex and GLEAM brands through a nationwide dealer network, supplies shared-mobility fleets and corporate customers, and provides after-sales service. The business is micro-cap (≈KRW 23bn market value; ≈KRW 32bn FY2025 revenue), highly seasonal and lumpy, swinging between losses and thin profits since the post-COVID demand collapse. Management is now pursuing B2B volume contracts, LMFP-battery e-bikes, digitalisation, and — with INNOX and NowIB Capital — M&A-led diversification into higher-value technology sectors. --- ### What the company does Alton designs, manufactures (directly and via its China operations) and sells bicycles and electric bicycles, and provides repair/after-sales services. Third-party data providers describe the company as making and selling sports and recreation bicycles in Korea and China, with a range covering e-bikes, smart bikes, MTB, road, hybrid, city, folding/minivelo, junior, ladies' and kids' bicycles, plus repair services (Simply Wall St company profile, 2025–26). Brands are alton, E-alton, INFIZA, ROADMASTER, Corex and GLEAM (Simply Wall St; StockHub). TheVC's analysis of 2023–2025 financials characterises the company as B2C-oriented, with revenue from bicycle sales and A/S (after-sales service), and with e-bikes as the expected primary revenue source given their higher value (TheVC, analysis dated 21 Apr 2026). ### Company's own characterisation In 2026 communications Alton presents itself as a "smart personal mobility" company (Asia Economy, 12 Jan 2026) and as "Korea's leading electric-bicycle company" seeking to keep an overwhelming No.1 position in domestic e-bikes (Asia Economy, 2 Apr 2026). The 2018 KOSDAQ IR deck claimed No.1 positions among domestic bicycle manufacturers, in domestic e-bikes, and in domestic shared bicycles, and set a long-range ambition of KRW 200bn revenue through "sustained growth and diversification" (Alton IR deck, 7 Nov 2018). the characterisation above relies on press coverage of that filing. ### Business model and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Revenue model | Overwhelmingly product sales (bicycles, e-bikes, parts/accessories); service revenue (A/S) is secondary; no subscription or licensing revenue disclosed | TheVC; Simply Wall St | | Reporting split | "Leisure products" (레저제품, manufactured goods) 86% and "leisure merchandise" (레저상품, purchased goods for resale) 14% of Q2 2026 revenue | Butler.works (Q2 2026) | | Channel mix | Historically dealer-led B2C; strategic shift to B2B (corporate, public-sector, shared-mobility operators) via a Special Sales Team (formerly a corporate-sales TF) | Sidae, 18 Mar 2026 | | Dealer ordering | Online B2B mall for dealers; target for B2B-mall ordering to reach ~90% of direct-sales revenue by 2026 | Asia Economy, 12 Jan 2026 | | Adjacent activity | Since H2 2022, sourcing of secondary-battery anode raw materials from China for INNOX affiliate TRS; 11.5% of H1 2023 revenue (2.3% at end-2022) | eToday, 22 Aug 2023; MTN, 27 Dec 2022 | ### Value-chain position Alton sits at the brand-owner/assembler stage of the bicycle value chain. It sources drivetrain components (e.g., Shimano groupsets on many models), motors and battery cells from third parties (historically Samsung SDI lithium-ion cells; from 2026 LMFP cells), fabricates frames and assembles in China and Korea, and distributes through franchised dealers and online channels. The 2014 company statement that it was the only domestic firm with an in-house factory running from frame raw material to finished bicycle (Sidae, 19 Feb 2014) indicates deeper vertical integration than most Korean peers; in 2025 it insourced a "putty" finishing process, which management credits for strengthening its profit base (Asia Economy, 12 Jan 2026). ### Customer types and end-markets | Customer type | Description | |---|---| | Retail consumers (via dealers/online) | Commuters, leisure riders, families, children; seasonal peak March–June | | Shared-mobility operators | Kakao Mobility e-bike fleet supply since 2019; KRW 16.8bn order in Dec 2022 (MTN, 27 Dec 2022) | | Large corporates | KRW 11.83bn e-bike supply contract with an unnamed domestic IT company, Jan 2026 (Sidae, 18 Mar 2026) | | Public sector | B2G contracts (TheVC lists 46 B2G contracts); police, fire-service and delivery e-bikes introduced 2018 (Insight, 2018) | | Affiliates | Battery-material sourcing for INNOX-group company TRS (MTN, 27 Dec 2022) | ### Independent characterisation Alton is best understood as a sub-scale, domestic-market consumer-durables brand whose fortunes now hinge on (a) e-bike demand cycles in Korea, (b) episodic large fleet/corporate orders that can equal 40%+ of a year's revenue, and (c) a controlling shareholder willing to inject capital and pursue diversification. Core bicycle profitability has been thin since 2022; FY2025's return to an operating profit relied materially on a bad-debt allowance reversal (≈KRW 0.82bn) and cost cuts rather than gross-margin expansion alone (Sidae, 18 Mar 2026).

Revenue$0.0B
Employees69
Market Cap$0.0B
Founded1994
Seongnam, South Korea
ALTEOGEN

ALTEOGEN Inc.

Premium
Information Technology

Alteogen is a Daejeon-based biopharmaceutical platform company. It is one of only two companies in the world that has commercialised a recombinant human hyaluronidase able to turn intravenous (IV) biologics into subcutaneous (SC) injections. The other is Halozyme of the US. Alteogen's enzyme, ALT-B4 (berahyaluronidase alfa), comes from its Hybrozyme™ platform. It is co-formulated in Merck & Co.'s Keytruda Qlex™ / Keytruda SC, the first SC PD-1 inhibitor, which the FDA approved in September 2025. Alteogen earns upfront payments, milestones, ALT-B4 supply revenue and royalties from ten global pharma licensees: MSD, Sanofi, Intas, Sandoz, Daiichi Sankyo, AstraZeneca, GSK/Tesaro, Biogen, an undisclosed partner and Novartis. Disclosed headline deal values total roughly KRW 16 trillion. The company also has biosimilars (Eylea biosimilar Eyluxvi®/Eyzenpi®, and a Herceptin biosimilar sold in China), a standalone hyaluronidase (Tergase®), ADC and long-acting platforms, and an early obesity candidate. Alteogen turned profitable in 2024. In 2025 it reported record revenue of KRW 215.9bn with a 49.5% operating margin. --- ### Company self-description In its press-release boilerplate and filings, Alteogen describes itself as a biopharmaceutical company that specialises in platform technologies for next-generation biologics. It names four areas: - **Hybrozyme™**, its human hyaluronidase platform for IV-to-SC conversion - **NexP™ fusion technology**, for long-acting biobetters - **NexMab™**, its antibody-drug conjugate (ADC) technology - **Antibody biosimilars**, developed in-house and with partners The FY2025 earnings disclosure (27 February 2026) gave three reasons for record results. First, it recognised more revenue tied to Hybrozyme, including milestones from Keytruda SC's FDA and EMA approvals and the AstraZeneca upfront. Second, ALT-B4 supply sales grew. Third, royalties from the Herceptin biosimilar Anqutuo (安曲妥) in China increased. ### Independent characterisation Economically, Alteogen is a B2B enabling-technology licensor and specialty API supplier, with a small but growing product business attached. **Licensing.** Partners pay Alteogen to co-formulate ALT-B4 with their own monoclonal antibodies, ADCs or other biologics. The goal is to deliver a large-volume SC dose in minutes instead of a 30–60 minute IV infusion. Merck's Keytruda Qlex is described as being given in about one minute. The licensor model has very high incremental margins: FY2025 gross margin was 76.7% and FY2025 operating margin was 49.5%. **Supply.** Alteogen is contractually responsible for clinical and commercial supply of ALT-B4 to most licensees, including MSD, AstraZeneca, Tesaro, Intas and Sandoz. It currently uses outside contract manufacturers (CMOs), some overseas. A KRW 253.2bn in-house drug substance / drug product plant in Daejeon is due by September 2028. **Products.** Alteogen sells Tergase® (recombinant human hyaluronidase) in Korea. It markets the aflibercept biosimilar ALT-L9 (approved in the EU as Eyluxvi® in September 2025 and in Korea as Eyzenpi®/아이젠피 in May 2026). It receives royalties on the trastuzumab biosimilar ALT-L2, which Qilu Pharmaceutical sells in China. **Pipeline optionality.** Earlier-stage programmes include NexMab ADCs (ALT-P7), NexP long-acting proteins (ALT-P1, a long-acting growth hormone), and a new long-acting conjugate platform. The lead candidate on that platform is ALT-M5, a once-monthly incretin fusion protein for obesity. ### Revenue model mix | Revenue stream | Nature | Visibility | |---|---|---| | Technical services / licensing (ALT-B4) | Upfronts, option fees, development and regulatory milestones, sales milestones, royalties | Upfronts are lumpy. Sales milestones and royalties now scale with Keytruda Qlex sales. | | ALT-B4 supply | Product revenue from enzyme supplied to licensees for clinical and commercial use | Grows with partner volume | | Merchandise and products | Tergase®, ALT-L9 and other goods sold through the former Alteogen Healthcare / Alteogen Biologics channels | Small so far | | Other technical services | Royalties (e.g., Anqutuo in China) and service contracts | Recurring, modest | A Butler summary of the H1 2026 semi-annual report gives the Q2 2026 revenue mix as about 88% ALT-B4 technical services, about 9% merchandise and about 3% other technical services. For FY2024, the Korea IR Council reported technical services of KRW 78.1bn (including KRW 2.4bn of other items), merchandise sales of KRW 10.0bn and product sales of KRW 14.7bn, for total revenue of KRW 102.9bn. ### Value-chain position, customers and end-markets **Value-chain position:** Alteogen sits upstream as the technology owner and API (enzyme) supplier. Partners run late-stage clinical development, regulatory filings and commercialisation. Alteogen manages enzyme regulatory files, CMC (chemistry, manufacturing and controls) and supply. **Customer types:** - Global innovator pharma: MSD, Sanofi, AstraZeneca/MedImmune, Daiichi Sankyo, GSK/Tesaro, Biogen, Novartis and one undisclosed company - Biosimilar and generic majors: Sandoz, Intas - Regional partners: Qilu (China), Cristália (Brazil), Kissei (Japan, ALT-L9) - Korean hospitals and clinics for Tergase **End-markets:** - Oncology: immuno-oncology (PD-1) and ADCs, which make up most of the value today - Immunology and neurology: Biogen (felzartamab and others) - Multiple modalities under the Novartis options - Ophthalmology: anti-VEGF biosimilar - Breast and gastric cancer biosimilars - Aesthetic and pain-adjunct hyaluronidase: Tergase - Prospectively, obesity (ALT-M5)

Revenue$0.2B
Employees30
Market Cap$12.6B
Founded2008
Daejeon, South Korea
Alpine

Alpine Housing Development Corporation Limited

Premium
Information Technology

| Attribute | Detail | Source | |---|---|---| | Legal name | Alpine Housing Development Corporation Limited | BSE filings | | Former names | None identified | BSE filings, aggregators | | CIN | L85110KA1992PLC013174 | BSE board-outcome letters (2019–2024) | | Incorporation date | 21 May 1992 (per Nirmal Bang profile); "1992" per CIN, Screener, MarketsMojo | Nirmal Bang; CIN | | Founding year (discrepancy) | Simply Wall St (S&P data) lists "founded 1991"; CIN and most sources show 1992 incorporation. 1991 likely reflects promoter group's pre-incorporation activity. | Simply Wall St vs CIN | | Incorporation jurisdiction | Karnataka, India (Registrar of Companies, Karnataka) | CIN prefix "KA" | | Registered office / HQ | No. 302, Alpine Arch, No. 10, Langford Road, Bengaluru, Karnataka 560027, India | BSE filings | | Telephone / email | +91-80-40473500 / 41144555; contact@alpinehousing.com | BSE letterhead | | Website | www.alpinehousing.com | Company | | Stock exchange | BSE Limited (Mumbai) – scrip code 526519, symbol ALPINEHOU | BSE | | NSE status (discrepancy) | Some aggregators list NSE symbol ALPINEHOU; Nirmal Bang and Voguestock state the stock is not listed/traded on NSE. Effective trading venue is BSE only. | Nirmal Bang; Voguestock; JM Financial | | ISIN | INE840D01015 | Nirmal Bang; MarketsMojo | | CUSIP | Not applicable (no US listing) | — | | Listing / IPO date (discrepancy) | GuruFocus records IPO date 1 August 1994; Simply Wall St records BSE listing as June 2002. Not reconciled in primary filings accessed. | GuruFocus; Simply Wall St | | Face value | ₹10 per share | JM Financial; Screener | | Shares outstanding | ~1.732 crore (17.32 million) | Simply Wall St; Screener (equity capital ₹17.32 Cr) | | Fiscal year end | 31 March | Filings | | Statutory auditor | RVKS and Associates, Chartered Accountants, Bengaluru (FRN 008572S); first appointed at 2017 AGM for a term to the 29th AGM (FY2022), re-appointed as retiring auditor at the 29th AGM (22 Sep 2022). Partner Pankaj Kumar R attended the 30th AGM (Sep 2023). Prior auditor: Rao & Venkatesulu (FRN 003108S). | BSE annual reports 2016, 2017, 2022; AGM proceedings 2023 | | Internal auditor | PradeepKumar B.H. & Associates, Bengaluru (appointed 29 May 2024 for FY2024-25) | BSE board outcome, 29 May 2024 | | Registrar & transfer agent | Cameo Corporate Services Ltd, Subramanian Building, No. 1 Club House Road, Chennai | MarketsMojo | | Company Secretary & Compliance Officer | Kurian Zacharias | BSE filings 2019–2026 | | Employees (latest) | 55 (Simply Wall St); 62 (GuruFocus) – sources conflict; 3-year trend not publicly disclosed in accessed sources | Simply Wall St; GuruFocus | | Market capitalisation (current) | ≈ ₹170 Cr at ₹98.0 close (Screener, late-Sep 2026 close); ScanX quotes ₹99.00 in October 2026. ≈ USD 20 million (indicative). | Screener; ScanX | | 52-week high / low | ₹156 / ₹74.1 | Screener | | Analyst coverage | Zero sell-side analysts | Simply Wall St | The identification details supplied (India; BSE; ticker ALPINEHOU.BO) resolve unambiguously to Alpine Housing Development Corporation Limited, a Bengaluru-based listed company with BSE scrip code 526519 and trading symbol ALPINEHOU. There has been no name change or migration of listing; the entity profiled is the same legal entity that has been listed on BSE since the 1990s. The Yahoo-style ticker in common use is 526519.BO; "ALPINEHOU" is the BSE symbol. Alpine Housing Development Corporation Limited is a promoter-controlled micro-cap that combines two businesses rarely seen under one roof: residential and commercial property development in Bengaluru, and the manufacture of pre-stressed mono-block concrete railway sleepers, SG-iron inserts and grey-iron castings supplied principally to Indian Railways. Founded and led for more than three decades by Chairman & Managing Director S. A. Kabeer, the company has completed roughly 44 lakh sq ft of construction across central, north and east Bengaluru, and operates a railway-sleeper unit near Narsapur on the city's outskirts. With FY2026 revenue of ₹72.88 Cr and net profit of ₹6.01 Cr, Alpine is tiny relative to Bengaluru's listed developers, but it has deleveraged sharply (borrowings down from ₹68 Cr in FY2018 to ₹14.6 Cr) and is pivoting toward an asset-light joint-development model—most notably a ~20 lakh sq ft North Bengaluru JDA—while seeking to scale its railway-sleeper franchise toward high-speed track applications. --- ### What the company does Alpine Housing operates through two reportable business segments—Housing Construction and Industry—and reports geographic segments as Karnataka and other States (S&P/AlphaSpread company description). Aggregator summaries of the annual report describe operations in three activity buckets: (1) construction and development of residential and commercial projects; (2) alloys (castings); and (3) concrete sleepers. **The company's own description** (as reproduced in its annual-report-based profiles on BSE-linked aggregators, paraphrased): the company is engaged in property development and building construction, and in the manufacture of railway concrete sleepers together with SG and grey iron castings. Its corporate profile further states that property development—encompassing condominiums, apartment buildings and commercial complexes—is the core business; that "Alpine Concrete Sleepers (ACS)" is a division manufacturing mono-block pre-stressed concrete sleepers for Indian Railways; and that "Alpine Alloys" is a Bengaluru-based castings division. An associated non-profit, the Alpine Educational Foundation, runs Alpine Public School; there is no indication in accessed filings that the foundation is consolidated into the listed company (Enrich Money company profile; IIFL summary). ### Business model and revenue model | Revenue stream | Nature | Model | Revenue recognition characteristics | |---|---|---|---| | Residential apartment sales | Product (real estate) | Sale of constructed units to retail buyers; historically on owned or JDA land | Lumpy; recognised on project/unit completion and handover under Ind AS 115; large inventory carried on balance sheet | | Commercial space | Product / occasional leasing | Sale (and historically investment property that is periodically sold) | One-off gains on sale of investment property recorded in other income (FY2026 other income fell owing to lower such gains – ScanX FY26 summary) | | Railway concrete sleepers | Product (B2G manufacturing) | Supply against Indian Railways / railway-zone tenders and purchase orders | Recurring but tender-dependent; order book reported at >₹50 Cr pending (FY2026 disclosure via ScanX) | | SG iron inserts & grey-iron castings | Product (B2B/B2G) | Components for sleepers (SG inserts) and general castings | Linked to sleeper volumes and industrial demand | | JDA revenue share (from FY2027+) | Licensing-like / revenue share | 30% share of total project revenue on the North Bengaluru JDA without bearing development expense (as reported) | Expected over 4–5 years from launch (targeted October 2026) | There is no subscription, licensing or service revenue in the conventional sense. The forthcoming JDA arrangement is economically closer to a land-plus-brand revenue share than to development, and will change the margin profile if it materialises as described. ### Value-chain position **Real estate:** Alpine sits at the developer layer—land acquisition (owned and JDA), approvals (BDA/BBMP), design, construction (largely self-executed, given its "construction" business description), marketing and sales. It is a member of CREDAI Bengaluru (logo on BSE letterhead). **Railway products:** Alpine is a Tier-1 direct supplier of finished sleepers to Indian Railways and a vertically integrated producer of its own SG-iron inserts (castings plant commissioned 2008), which gives it some control over a key component input. ### Customer types and end-markets | End-market | Customer type | Geography | |---|---|---| | Mid-income and upper-mid-income urban housing | Retail homebuyers, NRIs (not specifically disclosed) | Bengaluru (central, north and east micro-markets) | | Commercial real estate | Businesses, investors | Bengaluru | | Railway track infrastructure | Indian Railways (zonal railways, construction organisations) | Karnataka and other Indian states | | Industrial castings | Industrial OEMs / railway supply chain | India | ### Independent characterisation Alpine is best understood as a legacy Bengaluru developer with a cash-generative railway-products annex. The real estate side has been in harvest mode for most of the past decade—working inventory down, repaying debt and selling completed stock—while the sleeper unit has provided a steadier base of tender-driven revenue. The balance sheet tells the story: "Other assets" (dominated by real estate inventory and receivables) were ₹154 Cr at FY2026 against revenue of ₹73 Cr, inventory days as computed by Screener exceeded 1,700 days in FY2026, and debtor days were 213. Return on equity has been in the low-to-mid single digits for ten years (Screener: 10-year average ~5%). The strategic question for the company is whether the JDA pipeline and an automated high-speed-track sleeper plant can lift it out of this low-return equilibrium.

Revenue$0.0B
Employees55
Market Cap$0.0B
Founded1991
Bengaluru, India
Alphageo

Alphageo (India) Limited

Premium
Information Technology

Alphageo (India) Limited is a Hyderabad-headquartered, promoter-controlled geophysical services company that has positioned itself for more than three decades as India's oldest and largest private-sector provider of onshore seismic data acquisition, processing and interpretation services. Its customers are overwhelmingly Indian state-owned upstream companies — principally Oil and Natural Gas Corporation (ONGC) and Oil India Limited (OIL) — together with the Geological Survey of India (GSI) for mineral-exploration geophysics. The business is project-based and tender-driven: revenue swings sharply with the award and execution of large 2D/3D crew contracts, as illustrated by the climb to roughly INR 429 crore of revenue in FY2018 during the National Seismic Programme and the subsequent decline to INR 66 crore in FY2023. Today the company is a micro-cap (≈INR 162 crore market value) with a debt-free balance sheet, net worth of about INR 253 crore, and a stock trading well below book value, reflecting recent operating losses, contingent legal exposures, and uncertainty over order-book replenishment. --- ### What the company does Alphageo provides the "eyes" of hydrocarbon and mineral exploration: it designs seismic surveys, deploys field crews and recording equipment to acquire 2D and 3D seismic data over onshore (and, through its subsidiary, transition-zone/shallow-water) acreage, processes that data into subsurface images, and interprets those images to identify and rank drilling prospects. The company's filings describe its business as "Geophysical data acquisition, processing and interpretation services", and it reports a single operating segment under Ind AS 108 (Q1 FY2027 results, note 3). ### Company's own description (paraphrased from FY2024-25 Annual Report and filings) The FY2024-25 Annual Report presents Alphageo as a leading seismic services company serving ONGC, Oil India and the Geological Survey of India, operating across varied Indian geographies, and listed on the national exchanges. It frames its service menu as 2D/3D/3C seismic data acquisition, 2D/3D data processing and seismic interpretation, and it positions the company within national efforts to intensify domestic exploration for energy and critical minerals. The stated aspiration is to emerge as a leading seismic services and geophysical solutions player. (Paraphrase; the full annual report text is copyrighted and was only partially accessible.) ### Business model and revenue model | Dimension | Characterization | |---|---| | Revenue type | ~100% service revenue (project contracts); no product, subscription or licensing revenue disclosed | | Contract form | Fixed-price or unit-rate contracts (per line-km for 2D, per sq-km for 3D) won through public tenders issued by national oil companies (NOCs) and GSI | | Revenue recognition | Over the period of execution as survey volume is acquired (inferred from quarterly lumpiness tied to field seasons) | | Seasonality | Strong: Indian onshore field seasons are interrupted by monsoon (June–September), so Q2 (Jul–Sep) is typically the weakest quarter and Q4 (Jan–Mar) and Q1 (Apr–Jun) the strongest. FY2026 consolidated revenue by quarter: Q1 ≈ INR 40.8 cr, Q2 ≈ INR 5 cr, Q3 ≈ INR 17 cr, Q4 ≈ INR 49.3 cr | | Cost structure | Dominated by "geophysical survey and related expenses" (subcontracted labour, explosives/vibroseis operations, camp logistics, permitting) — INR 99.1 cr of INR 137.2 cr total consolidated expenses in FY2026; depreciation on recording equipment (INR 16.4 cr FY2026); a small fixed employee base (INR 14.2 cr FY2026) | | Capital intensity | High at peak (seismic recording channels, geophones, vibrators); capex has been minimal in recent years, implying an ageing but largely depreciated fleet | | Customer concentration | Extreme — essentially two to three government customers (ONGC, OIL, GSI); individual customer percentages are not disclosed in the sources reviewed | | Geography | India (100% of FY2025 revenue per sharpely.in segment data); a Dubai subsidiary is immaterial (Q1 FY2027 total income INR 0.25 cr) | ### Value-chain position Alphageo sits at the very front of the upstream value chain (exploration services), upstream of drilling, field development and production. It does not own exploration acreage itself (no participating interests disclosed), so it carries no commodity-price exposure directly; its exposure is indirect, via NOC exploration budgets and government exploration programmes (Open Acreage Licensing Policy blocks, National Seismic Programme, GSI mineral mapping). ### Customer types and end-markets | End-market | Customers (disclosed) | Notes | |---|---|---| | Onshore oil & gas exploration | ONGC, Oil India Limited | Bulk of revenue; contracts in Ganga-Punjab basin, Krishna-Godavari (KG) basin, Chhattisgarh, Gujarat, Rajasthan, Odisha, Assam/Arunachal Pradesh | | Mineral exploration (geophysical mapping) | Geological Survey of India (Southern Region, Hyderabad) | Gravity–magnetic and geophysical mapping surveys; an award worth INR 4.08 cr was reported (Zerodha/Reuters headline) | | Private and international E&P | Historically Hindustan Oil Exploration Company, GAIL (India), Petronas Carigali, and other private operators | From historical company presentations (2019) and IIFL history; no current private-sector contracts disclosed | ### Independent characterization Analytically, Alphageo is best understood as a single-country, single-service, government-tender contractor with a cyclical, lumpy order book. Its economics resemble those of a construction contractor more than an oilfield-technology firm: it competes largely on price and crew availability in L1 (lowest-bidder) public tenders, and margins depend on crew utilization and weather. Its competitive moat — long operating history, experience in difficult terrain (Himalayan foothills, North-East India), a large owned channel count, and NOC pre-qualification — is real but narrow. The company's balance sheet (debt-free, sizeable treasury investments) has allowed it to survive multi-year troughs, but the last two fiscal years show that, absent a large programme like the 2016–2019 National Seismic Programme, the business struggles to cover its fixed costs and depreciation.

Revenue$0.0B
Employees131
Market CapN/A
Founded1987
Hyderabad, India
Alpa

Alpa Laboratories Limited

Premium
Information Technology

Alpa Laboratories is a micro-cap, promoter-controlled Indian manufacturer of pharmaceutical finished dosage forms (FDFs) operating from a single WHO-GMP and ISO 9001-certified multi-dosage plant at Rau, near Indore. It produces injectables (liquid and dry-powder vials and ampoules), tablets, capsules, eye and ear drops, ointments, creams and gels for human use, and boluses, injections and intra-mammary infusions for veterinary use. It earns revenue through four channels: its own "Alpa" branded generics, a veterinary division, exports to emerging markets across Africa, Asia, Latin America and the CIS, and third-party contract manufacturing for domestic majors such as Cipla, Zydus, Lupin and Glenmark. With FY2026 revenue of about INR 106 Cr, virtually no debt and a treasury book of roughly INR 138 Cr that exceeds its market value, the company is better characterised as a cash-rich holding wrapped around a low-margin, sub-scale formulations business whose operating profitability has deteriorated sharply since FY2022. --- ### Company's own description Across its annual reports and exchange profile, the company describes itself as a WHO-GMP and ISO 9001:2000 certified company that manufactures a wide range of pharmaceutical finished dosage forms under its own brand and for other Indian and multinational companies, with a product range spanning ethical, generic and over-the-counter (OTC) drugs for both human and veterinary use (Screener key points citing alpalabs.in; CRISIL rating rationale, August 2025). For financial reporting, the company treats its entire operation as a single business segment, "Drugs and Chemicals" (FY2023 annual report, as cited by Screener). ### What the company does Alpa manufactures generic formulations in most conventional dosage forms at its Rau facility, which began commercial production in 1999 and has dedicated areas for liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels (IIFL company summary; MarketsMojo company CV). Its therapeutic coverage, as summarised in investor-database descriptions derived from company materials, includes anti-infectives (antibacterials, antibiotics, antifungals, antiprotozoals, antivirals), analgesics and anti-inflammatories, cough and cold, cardiovascular, anti-diabetic, nutritional supplements, psychotropics, skin care, and ear and eye care (Investing.com profile). ### Business model and revenue model | Division | Revenue model | Customer type | |---|---|---| | Branded Generic Division | Sale of own-brand products under the "Alpa" trademark through distributors, retail chemists, pharmacies and hospitals | Distributors, stockists, hospitals, retail pharmacies (India) | | Veterinary Division | Sale of animal-health formulations (boluses, injections, intra-mammary infusions) | Veterinary distributors, dairy/livestock channel | | Exports Division | Sale of formulations to importers and distributors in emerging markets, either under Alpa brands or partner brands | Overseas distributors, government/tender buyers (detail not disclosed) | | Contract Manufacturing Division | Loan-licence / third-party manufacturing for other pharma companies' brands | Indian pharma companies including Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt | The business is almost entirely product-based manufacturing revenue. There is no subscription or licensing revenue disclosed. Within product revenue, management historically organised marketing into four divisions (IIFL company summary): Division-level revenue split: not publicly disclosed in sources accessed. A material point for analysts: the "Alpa" trademark under which branded products are sold is registered in the name of Alpa Labs (India) Limited, a promoter-group company, not the listed entity (IIFL company summary). The listed company therefore does not own its principal brand asset, creating related-party dependency. ### Value-chain position Alpa sits in the downstream formulation stage: it buys active pharmaceutical ingredients (APIs) and excipients, converts them into finished dosage forms, and sells either into its own distribution channel or to brand owners. It does not manufacture APIs and is not known to conduct original drug discovery. Its economic position is that of a price-taker in commoditised generic molecules (penicillins, albendazole, paracetamol, tinidazole, etc.) where competition is intense and margins are thin. ### Independent characterisation The financial statements tell a story that differs materially from the "pharma manufacturer" label. In FY2025, other income (largely gains on investments) of INR 23.35 Cr was nearly five times operating EBITDA of INR 4.75 Cr (Anand Rathi, FY2025). In FY2026, other income of INR 15.76 Cr compared with operating EBITDA of INR 3.29 Cr. Consolidated investments and short-term securities rose from INR 70.3 Cr (FY2022) to INR 137.9 Cr (FY2026) (StockAnalysis balance sheet). The company has paid no dividend in at least a decade (Finanzen dividend calendar). In effect, the operating business generates modest cash that is accumulated in a growing treasury portfolio, and reported earnings are driven mainly by that portfolio's returns. In Q1 FY2027 (June 2026 quarter), the operating line turned negative (operating loss of INR 3.96 Cr), with other income of INR 5.77 Cr keeping the company profitable (Screener quarterly). ### End-markets served India domestic generics (branded and trade generics); Indian animal health; emerging-market exports (Philippines, Iran, Iraq, Sierra Leone, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Sri Lanka per IIFL; also South and Central America, Africa, Asia and CIS countries including Russia, Ukraine and Kazakhstan per Investing.com and Stoxray profiles); and B2B contract manufacturing for Indian pharma majors.

Revenue$0.0B
Employees410
Market CapN/A
Founded1967
District Indore, India
Almondz

Almondz Global Securities Limited

Premium
Information Technology

Almondz Global Securities is a New Delhi-based diversified financial-services holding company that has turned into a three-legged conglomerate. The original legacy is a mid-tier Indian investment bank and broker founded in 1994, which still provides debt and equity capital-markets advisory, merchant banking, broking and wealth advisory. The largest revenue engine is now infrastructure consultancy, run through its 58.52%-owned subsidiary Almondz Global Infra-Consultant Limited (AGICL). AGICL supplies project-management, supervision and advisory services, mainly to government infrastructure agencies, and contributed about 64% of consolidated revenue in FY2026. The largest profit contributor is a 40.99% equity-accounted stake in Premier Green Innovations Private Limited (PGIPL), a grain-based fuel-ethanol producer with 485 KLPD of installed capacity in Himachal Pradesh and Odisha. PGIPL accounted for about 58% of consolidated net profit in FY2026. Management is now restructuring the group through a proposed demerger and separate listing of the infrastructure-advisory business. --- ### What the company does AGSL runs three economic verticals. Management names them in its Q1 FY2027 press release (28 July 2026): 1. **Financial services.** Wealth advisory and broking, corporate advisory and merchant banking, plus proprietary debt and equity market operations. 2. **Green fuel.** Production of grain-based ethanol and distillery operations through the joint venture/associate PGIPL. AGSL holds 40.99% and its parent Avonmore holds a further 8.88%. 3. **Infrastructure advisory.** Project-management consultancy, feasibility studies, design and supervision, and authority's/independent engineer roles, delivered through AGICL. For statutory segment reporting under Ind AS 108, the consolidated accounts present six segments: (a) Debt and equity market operations; (b) Consultancy and advisory fees; (c) Wealth advisory / broking activities; (d) Finance activities; (e) Healthcare activities; (f) Others. The green-fuel business does not appear as a revenue segment. Because PGIPL is an associate, its contribution enters the income statement only as "share of profit of equity-accounted investees" (₹16.60 crore in FY2026). ### The company's own description The CARE rating rationale, drawing on company disclosures, describes AGSL as the flagship of the Almondz Group. Its activities are listed as corporate-finance advisory, investment banking, trading and investment in debt and equity securities, equity/commodity/fixed-income broking, distribution of financial products, wealth management and NBFC activities. Through subsidiaries and JVs it has also expanded into infrastructure consultancy (AGICL) and green-fuel manufacturing (PGIPL). Screener's summary of the annual report describes the group as delivering "360-degree" advice across infrastructure (highways, power, airports, urban and water), investment banking, institutional equities, research, broking, wealth management and depository services. ### Revenue model | Revenue type | Source | Character | FY2026 weight (consolidated revenue from operations ₹190.43 cr) | |---|---|---|---| | Fee and commission income: consultancy | AGICL infrastructure advisory contracts (milestone/time-based billing, about 80% from government and government-backed clients per CARE) | Service, contract-backed, multi-year | ₹154.72 cr in the "Consultancy & advisory fees" segment (about 81% of segment revenue; CARE puts infrastructure alone at about 64% of operating income) | | Fee and commission income: capital markets | Arrangement fees on debt and equity issuance, merchant banking, M&A and corporate advisory | Transactional, cyclical | Included in the consultancy segment and not separately disclosed | | Brokerage and distribution | Equity, commodity and debt broking; wealth and product distribution | Transactional / AUM-linked | ₹12.85 cr (Wealth advisory / broking segment) | | Treasury / trading ("Others" line plus fair-value changes) | Proprietary debt and equity positions; gains on strategic stake sales | Mark-to-market, volatile | ₹22.21 cr segment revenue (Debt & equity market operations), offset by ₹16.89 cr of fair-value losses booked in expenses | | Interest and dividend | Treasury and loan book | Recurring, small | ₹2.15 cr | | Share of associate profit (below the line) | PGIPL ethanol | Equity-method income | ₹16.60 cr (not revenue) | There is no product, subscription or licensing revenue. The group is a service and investment business. Manufacturing exposure is held only indirectly through the associate. ### Value-chain position and customers **Infrastructure advisory:** AGICL sits upstream of EPC contractors as an owner's-side consultant (project-management consultant, independent engineer, authority's engineer, detailed project report preparer). Its customers are central and state infrastructure agencies (roads, railways, urban, industrial-park development such as Odisha IDCO), multilateral-funded projects and private concessionaires. **Financial services:** AGSL acts as an intermediary between issuers (corporates, PSUs, state entities raising debt) and investors (institutions, HNIs, retail). It is strongest in debt-capital-markets arrangement, a historical Almondz niche. **Green fuel:** PGIPL is a midstream processor that converts grain (broken rice/maize) into fuel ethanol and sells it to oil marketing companies (OMCs: IOCL, BPCL, HPCL) under the Government of India's Ethanol Blended Petrol (EBP) Programme. Its by-products include DDGS. Sales are tender-allocated, with the price administered by the government. ### Independent characterisation On paper AGSL is a "securities" company, but economically it now operates as a holding company for an infrastructure consultancy and an ethanol producer, with a sub-scale broking and investment-banking franchise attached. FY2026 shows this clearly: - The legacy wealth/broking segment shrank from ₹20.29 cr to ₹12.85 cr in revenue. - Debt and equity market operations broke even only because a gain on the stake sale offset fair-value losses. - Group earnings depended on AGICL execution and PGIPL's equity-accounted profit. The proposed AGICL demerger, which would hand AGSL shareholders AGICL shares directly, would make AGSL more clearly a financial-services company plus an ethanol stake. CARE explicitly identifies dependence on these two non-core entities as a rating constraint.

RevenueN/A
Employees180
Market CapN/A
Founded1994
Mumbai, India
Allied

Allied Digital Services Limited

Premium
Information Technology

Allied Digital Services is a Mumbai-headquartered, promoter-controlled mid-tier IT infrastructure services company that sits between India's large-cap IT majors and pure-play domestic system integrators. Its economic engine is multi-year, annuity-style managed services — digital workplace, end-user computing, service desk, cloud and infrastructure management, and cybersecurity — delivered predominantly to large overseas enterprises (about 73% of Q1 FY27 revenue came from outside India). Layered on top is a project-based "Master System Integrator" business in India, best known for Safe City and Smart City command-and-control deployments, beginning with the Pune City Surveillance project in 2015. At roughly ₹1,000 Cr of trailing revenue, ADSL is sub-scale against global infrastructure outsourcers but has a reference base of Fortune 100 clients and a growth record of ~22% revenue CAGR over FY21–FY26. Its investment case is constrained by thin operating margins, elevated receivables, audit qualifications in FY25–FY26, and a heavily family-anchored board. --- ### What the company does ADSL designs, deploys, manages and supports IT infrastructure and end-user technology for large enterprises and government bodies. The company's own framing — repeated across its investor presentations since 2023 — positions it as a "Digital Transformation Architect, Global Managed IT Service Provider and Master Systems Integrator." Exchange-filed results notes describe the group as engaged in IT and ITeS services as a global managed service provider and systems integrator, offering the full spectrum of infrastructure solutions and services to clients across 70 countries (Q2 FY26 integrated filing, November 2025). Independently characterized, ADSL operates two distinct businesses under one roof: 1. **A recurring managed-services business (≈78–83% of revenue)** — multi-year contracts to run digital workplaces, service desks, end-user devices, data-centre and cloud infrastructure, networks and security operations for enterprise clients, largely in the US, Europe, Middle East and Australia. The ₹420+ Cr five-year contract awarded in August 2025 by a European multinational pharmaceutical company to transform the digital workplace for over 120,000 employees across 66 countries is archetypal (Company press release, 6 Aug 2025). 2. **A project/solutions business (≈17–22% of revenue)** — turnkey system integration, most prominently Safe City/Smart City surveillance and Integrated Command & Control Centres (ICCC) for Indian state and municipal governments, plus hardware-plus-integration projects for enterprises. These are lumpy, tender-driven, working-capital intensive and carry implementation risk, but convert into multi-year operations and maintenance (O&M) annuities. ### Business and revenue model | Revenue model dimension | ADSL characterization | Evidence | |---|---|---| | Services (recurring) vs Solutions (projects) | Services 78% / Solutions 22% (Q4 FY26); Services ₹215 Cr / Solutions ₹45 Cr in Q1 FY27 (≈83% / 17%) | Q4 FY26 deck; Q1 FY27 results as summarized | | Product vs service | Overwhelmingly services; proprietary software platforms (ADiTaaS, FinoAllied) are embedded in service delivery; standalone licence revenue n.d. | Company product descriptions | | Subscription / SaaS | ADiTaaS marketed as SaaS ITSM/ESM platform; revenue contribution n.d. | Company / FMP profile | | Hardware pass-through | Present within Solutions (cameras, servers, network gear for Safe City projects); inventory days 31 in FY26 | Screener ratios | | Contract tenor | Services contracts typically multi-year (3–5+ years); Safe City projects run 6 years including O&M | Pune Safe City disclosure Oct 2024; pharma contract Aug 2025 | | Pricing | Fixed-price contracts are a key audit matter (revenue recognition on fixed-price contracts) | Auditor's report (Key Audit Matters) | ### Value-chain position ADSL operates in the delivery and operations layer of the IT value chain: it typically does not manufacture hardware or own hyperscale platforms; it partners with OEMs and software vendors, integrates their products, and earns margin on design, deployment, ongoing management and support labour. In Indian government projects it acts as the prime system integrator (MSI), sub-contracting civil works and sourcing equipment. ### Customer types and end-markets | Customer type | FY25 (₹ Cr, derived) | FY26 (₹ Cr) | FY26 YoY | Source | |---|---|---|---|---| | Government | 242 (derived from FY26 value and -6% growth) | 227 | -6% | FY26 press release / deck via Business News Today | | Non-Government (Enterprise) | 566 (derived from FY26 value and +31% growth) | 741 | +31% | Same | End-markets disclosed by CRISIL and the company include public administration, healthcare and pharmaceuticals, BFSI (banking, financial services, insurance), oil and gas, retail, technology and manufacturing. Recent order wins cover a European pharma major, a leading Indian private-sector insurer, a state healthcare authority, a Midwest US client, government gas utilities, and an Indian central-government body under the Ministry of Commerce (Q3 FY26 and Q1 FY27 disclosures).

Revenue$0.1B
Employees3,500
Market CapN/A
Founded1984
Mumbai, India
Alliance

Alliance Healthcare Group Limited

Premium
Information Technology

Alliance Healthcare Group is a physician-founded Singapore healthcare platform with roughly S$87m in revenue. It combines six businesses that are usually run separately: a 16-clinic "My Family Clinic" GP chain plus a medical centre; private specialist clinics in orthopaedics, ENT and general surgery; a medical third-party administrator (Alliance Medinet) that manages outpatient and specialist benefits for insurers and corporates across a partner network of more than 2,000 facilities; an HSA-licensed pharmaceutical wholesaler; a home-care and telemedicine arm (Jaga-Me, now 98.4% owned) that supports five public hospitals under the Ministry of Health's MIC@Home programme; and a small institutional health-IT business. Its core thesis is that owning both the payer-side administration and the provider-side delivery lets it steer patient volume through its own network and capture data on utilisation. The company is micro-cap (about S$37m), founder-controlled (about 68%), almost entirely domestic (98% Singapore revenue), thinly traded and uncovered by sell-side research. FY2026 brought a profit inflection. --- ### Company's own description (paraphrased from Annual Report 2025) The Annual Report 2025 describes Alliance as a trusted medical brand that spans GP and in-house specialist clinics, a corporate health-solutions organisation, a wholesale pharmaceutical company serving the region, and a mobile and home-care provider. It calls itself "physician-led and physician-driven". The report says the company aims to be a next-generation healthcare company that uses technology to deliver cost-effective, personalised services, and that utilisation data helps corporate clients and insurers get better value from their health spending. Its stated vision is to empower people to lead healthy lives through an integrated ecosystem of care. Its stated mission is to be a healthcare innovation company that personalises and simplifies community care delivery. In the FY2025 Chairman's Message, management describes a post-IPO "strategic pivot" away from a traditional brick-and-mortar model towards a digitally enabled platform that links self-owned and partner facilities into a single health ecosystem. ### Independent characterisation On the evidence of its segment accounts, Alliance is best understood as a Singapore managed-care administrator with a captive provider network attached, rather than as a clinic chain. **Managed healthcare solutions:** (Alliance Medinet plus in-house corporate clinics) is now the largest segment by revenue (25.4% in FY2026) and by far the largest by profit. It generated S$3.25m pre-tax in FY2026, about 85% of group PBT of S$3.82m. It also carries most of the group's balance sheet: S$70.8m of S$102.8m segment assets, mainly claims receivables offset by claims payables to panel providers. **GP clinic services:** (S$20.1m) and specialist care services (S$19.8m) are the provider layer. Both have thin margins, and both are sensitive to doctor retention and start-up costs. **Pharmaceutical services:** (S$14.5m) is a wholesale distribution business with an overseas export component. It is shrinking (−10.6% in FY2026). **Mobile and digital health services:** (Jaga-Me home care plus HeyAlly telemedicine, S$7.9m) is the main growth investment. It reached EBITDA breakeven in FY2026 for the first time since the COVID-19 boom faded. **Others:** (S$2.8m) is now mostly a single institutional IT contract: the clinic management system for the Health Promotion Board's Youth Preventive Service (YHCMS). ### Business and revenue model | Model element | Description | FY2026 revenue (S$m) | Share of group (%) | |---|---|---|---| | Fee-for-service medical services | GP and specialist consultations, procedures, health screening, radiology | 39.93 | 45.7 | | Managed-care / TPA services | Administration fees and managed-care revenue from insurers and corporates; in-house corporate clinic contracts | 22.14 | 25.4 | | Product sales | Wholesale of medicines, supplements and medical devices | 14.54 | 16.6 | | Mobile and digital services | Home nursing and medical visits (MIC@Home), telemedicine, health screening | 7.90 | 9.0 | | Others (incl. project/IT revenue) | YHCMS clinic-management system contract (S$2.7m recognised in FY2026); recognised partly over time | 2.84 | 3.3 | Source: FY2026 results, Note 4.2 (disaggregation of revenue). In FY2026, S$1.96m of revenue was recognised over time and the balance at a point in time. There is no subscription or licensing revenue line of material size. The IT contract revenue in "Others" behaves like a project, and SGiMED's software-as-a-service income sits in an associate, so it is not consolidated. ### Value-chain position Alliance sits in the middle of the private outpatient value chain: **Upstream:** it procures pharmaceuticals and devices from principals and distributors through Alliance Pharm, which also supplies the group's own clinics. **Midstream:** it delivers primary, specialist, home and tele-care through owned facilities, and contracts a panel of more than 2,000 third-party facilities (FY2026 commentary). Those include GP clinics, screening centres, specialist and TCM clinics, labs, imaging centres, a private hospital and home-care providers. **Payer interface:** through Alliance Medinet it administers claims for insurers and employers, steering visits into the network at pre-agreed rates. Ecosystem visits were about 1.25m in FY2024, more than 1.45m in FY2025 and about 1.55m in FY2026 (FY2026 results, commentary). ### Customer types and end-markets | Customer type | Segment(s) served | Evidence | |---|---|---| | Insurers | Managed healthcare | Eight insurer arrangements at IPO (2019). Named partners over time include Great Eastern, AXA (now HSBC Life), QBE, Aviva (now Singlife), Cigna Europe and EQ Insurance (AR2025 milestones; SGX announcement 31 Jul 2019) | | Corporate employers | Managed healthcare, GP, digital | More than 2,000 corporations served at IPO (The Edge, 24 May 2019). In-house corporate clinics for SMRT, GlobalFoundries and Marina Bay Sands (AR2025 clinic list) | | Public hospitals / health clusters | Mobile and digital, managed healthcare | MIC@Home partner for five government-restructured hospitals (FY2026 commentary); NUHS@Home external nursing contract (SGX, 8 Aug 2024) | | Government agencies | Others | Health Promotion Board YHCMS contract (FY2024 to FY2026 results) | | Individual patients | GP, specialist, digital | 16 My Family Clinic GP outlets, Alliance Medical Centre, specialist clinics, HeyAlly app | | Hospitals, pharmacies, clinics, drug manufacturers (Singapore and overseas) | Pharmaceutical | AR2025 Sustainability Report, "Our Business" |

Revenue$0.1B
Employees395
Market CapN/A
Founded1994
Singapore
Alliance

Alliance Developpement Capital SIIC

Premium
Information Technology

ADC SIIC is a Brussels-domiciled, Paris-listed real estate holding company that, despite its SIIC label and residential-REIT industry classification, is today economically a concentrated vehicle owning the majority of the walls of a 58-key, four-star hotel at 218–220 rue du Faubourg Saint-Honoré in Paris's 8th arrondissement, plus the bare ownership of a 270 m² apartment in the 7th, together appraised at EUR 35.0M. Roughly 40% of its gross asset value sits outside France in two equity-accounted holdings: a 27% stake in Swiss holding company Dual Holding (EUR 20.0M) and 50% of Hillgrove Investments Group, which owns a house in central London (EUR 5.0M). Revenue of about EUR 1.06M comes from a single hotel tenant with whom the company has been in multi-front litigation since 2018. The group is part of the Alain Duménil constellation of small Paris-listed foncières (with Acanthe Développement and FIPP) and trades at a persistent discount of roughly 80–85% to reported NAV. --- ### Company's own description In its regulated releases the company describes itself as a Belgian-law foncière listed in Compartment C of Euronext Paris, managed by an Administrateur Délégué. Its interim management reports state that the group generates all of its revenue in France and in the real estate sector, and that revenue excludes the UK and Swiss holdings, which are equity-accounted (H1 2024 interim report, Section I). Its management reports also describe a strategy of "dynamic conservation" of its property holdings and close follow-up of its tenant litigation (H1 2024 interim report, Section VII). Third-party profile services paraphrase the company's historical self-description as an investor in residential, commercial, hotel and office property in Paris and its suburbs, following an opportunistic investment policy driven by market availability and financing conditions (financialfilings.com company profile). ### Independent characterisation That residential/opportunistic description is now largely historical. On the evidence of FY2021–H1 2026 filings, ADC SIIC is best characterised as: 1. **A single-asset hotel landlord.** Effectively 100% of consolidated revenue is rent/occupation indemnity paid by Hôtel Faubourg Champs-Élysées ("HFCE"), operator of the hotel at 218–220 rue du Faubourg Saint-Honoré. The lease reached its renewal date on 28 February 2020; the landlord subsidiary (Bassano Développement, 84.99% owned) served a refusal to renew without eviction indemnity on 19 August 2020, and the tenant has since paid an occupation indemnity pending litigation (H1 2024 interim report, note 7.1). 2. **A passive holder of a bare-ownership residential interest.** The 270 m² apartment at 4–6 avenue Élisée Reclus (Paris 7e) generates no income; it is occupied by its usufructuary, who has no link to the group (H1 2024 interim report, segment note). 3. **A minority investor in family-linked holding companies.** Dual Holding (Fribourg, Switzerland), 27% held via Swiss subsidiary Gepar Holding, with the remaining 73% held by Valérie Gimond Duménil and Laurence Duménil; and Hillgrove Investments Group (Luxembourg), 50% held via Cofinfo, with the other 50% held by Kentana, a FIPP group subsidiary (H1 2024 interim report, notes 6.3.1–6.3.2). 4. **A litigation-heavy legacy shell.** Two subsidiaries (Kerry, Cofinfo) exist mainly to pursue or defend long-running disputes concerning former Paris buildings (expropriation at 48 rue du Faubourg Poissonnière; former squat at 3–5 rue Godefroy Cavaignac) (H1 2024 interim report, note 5.1). ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | 100% property rental / occupation indemnity plus recharged service charges; no product, subscription or licensing revenue | | Customer types | One commercial tenant (hotel operator HFCE); historically also hotel tenant NRF (liquidated 2015) and the Salons Saint-Honoré event-space tenant | | End-market | Paris luxury/upscale hotel real estate (Golden Triangle / Faubourg Saint-Honoré); indirectly Swiss/Italian property and financial assets (Dual Holding) and Mayfair residential (Hillgrove) | | Value-chain position | Owner-lessor of hotel walls ("murs"); no hotel operating exposure | | Income beyond rent | Equity-method share of associates' results; dividends and fair-value changes on small holdings of listed shares in related companies FIPP and Acanthe Développement | | Cost structure | Overheads c. EUR 0.6M p.a. (staff, fees, listing costs, management fees to related party Ardor Capital), interest on a EUR 13.4M current-account advance from associate Dual Holding | | Tax regime | French SIIC regime (opted 2004) applied via the French permanent establishment, currently challenged by the French tax authorities (see Sections 18–19) |

RevenueN/A
Employees2
Market CapN/A
Founded1991
Saint-Josse-ten-Noode, Belgium
Alkem

Alkem Laboratories Limited

Premium
Information Technology

Alkem Laboratories is India's sixth-largest pharmaceutical company by value in the Indian Pharmaceutical Market (IQVIA SSA MAT March 2026) and third-largest by prescriptions (SMSRC MAT February 2026), with a five-decade franchise built on acute-care mega-brands — most notably Clavam (amoxicillin-clavulanate), the PAN pantoprazole family (the second-largest brand family in the IPM), Taxim and A to Z. It has led the anti-infectives therapy area in India for more than 15 years. Roughly two-thirds of FY26 revenue of INR 147.1 bn came from India, with the balance from a US generics business (Ascend Laboratories, ~20% of sales) and a fast-growing non-US international portfolio (~12%). Under a promoter-family governance model, Alkem is repositioning toward chronic therapies (anti-diabetics including semaglutide, neuro, derma, cardiac), biosimilars and CDMO via Enzene Biosciences, and medical devices via Alkem MedTech — the last now anchored by the July 2026 acquisition of a controlling stake in Swiss structural-heart device maker Occlutech. It carries a net-cash balance sheet (INR 57.6 bn at 30 June 2026). --- ### Company's own description In its Q1 FY27 press release (14 August 2026), Alkem describes itself as the sixth-largest pharmaceutical company in the Indian market with more than 50 years of heritage, a dominant position in anti-infectives, gastrointestinal, pain management and supplements, and a growing chronic portfolio spanning diabetes, neurology, dermatology and urology. It states that it operates 20 manufacturing facilities and R&D centres producing generic formulations, active pharmaceutical ingredients (APIs) and biosimilars, and that outside India it has a meaningful presence in the US, Latin America, Australia, Europe and several Asian markets. Its corporate purpose line is "Inspiring Healthier Lives". For statutory segment reporting the company reports a single business segment — pharmaceuticals — with geographic disclosure of India and international (Morningstar profile; company filings). ### Independent characterization Alkem is best characterized as a domestic branded-generics franchise with three option-value adjacencies bolted onto a cash-generative core: 1. **India branded generics (≈62–63% of sales after trade generics carve-out).** Prescription-driven, field-force-led promotion of branded generics through ~14,000 medical representatives to general practitioners, consulting physicians and specialists. Pricing is partially regulated: BOB Capital Markets estimated that roughly 30% of sales fall under India's National List of Essential Medicines (NLEM) price controls (Q3 FY25 Result Review, 8 February 2025). 2. **India trade generics (historically ~20% of domestic sales).** Unbranded or lightly branded generics sold through distributors/retailers rather than promoted to doctors; carved out into wholly owned subsidiary Alkem Wellness Limited effective 1 October 2025. Alkem describes itself as a "leading player in the trade generics segment" (Q4 FY26 presentation). 3. **US generics (≈20% of sales).** Oral solids and other generic formulations sold under the Ascend Laboratories front end, supplied from Indian plants (Daman, Baddi) and US API capacity (California). Includes Enzene's US CDMO revenue in reported US figures (Q4 FY26 presentation footnote). 4. **Non-US international (≈12% of sales; fastest-growing).** Branded and generic sales in Australia (Pharmacor), Chile/Latin America, Philippines, Kazakhstan, Europe and the Middle East (new Saudi JV and Dubai subsidiaries). 5. **Biosimilars and CDMO (Enzene Biosciences).** Biosimilar development and manufacturing in Pune, India and a US CDMO facility; 6–7 biosimilars in the Indian portfolio per BOB Capital Markets (Q1 FY27 Result Review, 14 August 2026). 6. **Medical devices (Alkem MedTech).** Orthopaedic implants (Bombay Ortho, renamed Alkem MedTech Ortho; Advita Ortho/Exactech licensing in India) and, since July 2026, structural-heart occluders via Occlutech. Management stated MedTech contributed less than 1% of revenue before Occlutech (Q4 FY26 earnings call, 28 May 2026). ### Revenue model and value-chain position | Dimension | Characterization | |---|---| | Product vs. service mix | Overwhelmingly product revenue (finished dosage formulations, APIs, nutraceuticals, biosimilars, implants). Service revenue limited to Enzene CDMO (contract development/manufacturing) — not separately disclosed | | Subscription / licensing | No subscription revenue; in-licensing and out-licensing deals exist but licensing income not separately disclosed | | Value chain position | Vertically integrated: API manufacture (Ankleshwar, Mandva, California) → formulation (Baddi, Daman, Sikkim and others) → own distribution and field-force marketing in India; US front end via Ascend | | Customer types | Indian physicians (prescribers), chemists/distributors/stockists, hospitals; US wholesalers, retail pharmacy chains, group purchasing organisations; international distributors and tender buyers; CDMO clients (biopharma companies) | | End markets | Human pharmaceuticals (acute and chronic), nutraceuticals/consumer wellness, biologics, orthopaedic and cardiovascular devices | | Other operating income | FY26 "revenue as reported" including other income was INR 152,956 M vs. revenue from operations of INR 147,123 M (StockAnalysis standardized) |

Revenue$1.7B
Employees21,057
Market CapN/A
Founded1973
Mumbai, India
Alkali

Alkali Metals Limited

Premium
Information Technology

Alkali Metals Limited is one of India's oldest specialist producers of sodium-metal derivatives, a niche class of highly reactive reagents (sodium amide, sodium hydride, sodium alkoxides, sodium azide) used to build drug molecules. Founded in 1968 as a state-backed joint venture in Hyderabad, it has evolved into a promoter-controlled, three-plant manufacturer whose portfolio spans sodium derivatives, picoline/pyridine-based heterocycles (amino-, acetyl- and aminomethyl-pyridines), tetrazoles, cyclic compounds, contract "campaign" fine chemicals and a small slate of APIs from a USFDA-inspected unit in Visakhapatnam. Its customers are predominantly pharmaceutical and agrochemical manufacturers in India and overseas, with exports historically 50–62% of sales. The company is sub-scale (FY2026 revenue INR 93.03 Cr), cyclically profitable, working-capital intensive and governed by a founding family that controls 69.59% of equity. Its investment case rests on technical niche depth and export relationships, offset by thin margins, governance friction and succession uncertainty. --- **What the company does.** Alkali Metals manufactures and sells chemicals. Its exchange letterhead describes it as a manufacturer of "Sodium Amide, Sodium Alkoxides, Sodium Hydride, Sodium Azide, Tetrazoles, Amino Pyridines, Pyridine Derivatives, Cyclic Compounds, Fine Chemicals, Intermediates for pharmaceuticals and Active Pharmaceutical Ingredients" (FY2026 results filing, 26 May 2026). ICRA characterises the company as an ISO 9001/14001-certified maker of sodium metal derivatives, picoline-based compounds and cyclic chemicals, supplied primarily to pharmaceutical companies for bulk-drug production (ICRA rationale, Dec 2024). **Company's own segment framing.** In its Ind AS 108 segment note the company states that, because it is "predominantly engaged in the manufacture and sale of chemicals where the risks and returns associated with the products are uniform," its only reportable segments are geographic (Domestic and Export), based on customer location (FY2026 audited results, Note 6). **Business model.** The company operates a batch, multi-product, made-to-order chemical manufacturing model: **Catalogue reagents:** (sodium derivatives) sold repeatedly to bulk-drug makers who use them as bases, reducing agents or azide sources in API synthesis. **Heterocyclic intermediates:** (pyridine derivatives, tetrazoles, cyclic compounds) sold as building blocks to pharma and agrochemical customers. **Campaign fine chemicals:** higher-margin, customer-specific molecules produced in discrete campaigns, often for export customers. ICRA explicitly attributed FY2024–FY2025 margin pressure partly to "lower sales of high margin campaign products (fine chemical)" (ICRA, Nov 2024). **APIs:** from the Visakhapatnam (JNPC) unit, which received USFDA cGMP status in May 2019 (ICRA, Nov 2019). **Revenue model mix.** Essentially 100% product sales. There is no disclosed service, subscription or licensing revenue. Contract manufacturing is embedded within product sales (campaign products) and is not separately disclosed. **Value-chain position.** Alkali Metals sits in the upstream-to-midstream portion of the pharmaceutical value chain: it buys basic raw materials (sodium metal or precursors, picolines/pyridine bases, solvents, ammonia, hydrogen-handling infrastructure) and converts them into reagents and intermediates sold to API manufacturers. It also participates one step further downstream through its own API slate. It does not sell finished formulations. **Customer types and end-markets.** ICRA (Sep 2021) noted that the top products together contributed roughly two-thirds of sales in FY2020–FY2021 and that one category accounted for 42% of FY2021 sales, indicating meaningful product concentration. **Independent characterisation.** Alkali Metals is best understood as a technically differentiated but commercially sub-scale niche reagent house. Handling metallic sodium and its derivatives (pyrophoric hydrides, explosive azides) requires specialised plant, safety systems and permits, which constitutes a genuine barrier to casual entry. However, the company has not converted this niche into scale: revenue has oscillated between INR 55 Cr and INR 98 Cr for a decade, operating margins have rarely exceeded 13.8%, and returns on equity have averaged ~2% over 10 years (Screener.in compilation). Its earnings are highly sensitive to (a) the timing of export campaign orders, (b) inventory build/release (inventory days 223–494 over FY2015–FY2026), and (c) raw-material and power costs. The business behaves like a job-shop with a quality reputation rather than a platform specialty-chemicals franchise.

Revenue$0.0B
Employees107
Market CapN/A
Founded1968
Hyderabad, India
AUDROC

AUDROC Limited

Premium
Information Technology

AUDROC Limited is a revived shell. It emerged from the Corporate Insolvency Resolution Process (CIRP) of Alka India Limited, a dormant Mumbai textile trading and commission-agency company. The NCLT Mumbai Bench approved Mr. Jatinbhai Ramanbhai Patel's resolution plan on 7 February 2025. The plan extinguished the erstwhile promoters' holding, cut public shareholders to 5% of restructured capital, and handed control to a new Gujarat-based promoter group. Under that group the company restarted revenue in Q4 FY2026, generating ₹2.51 Cr, mainly from agro-commodity trading. It renamed itself AUDROC Limited, widened its objects to agriculture and FMCG, and announced plans to acquire seven Gujarat food and agro companies through share swaps. Those plans were withdrawn in April 2026. It is now raising up to ₹80 Cr through convertible warrants. The investment case rests entirely on whether the promoters can turn a listed shell with ₹1 face value shares into a real agri-commodity and food business. Governance and execution risk are extreme. --- ### Company's own description The company's FY2026 annual report (summarised by Kotak Neo and ICICIdirect from the filing) gives three facts: - Historically, the company traded and manufactured cotton, yarn, fabrics, and import/export of yarns, rayon, fibres and cotton textiles. - FY2024-25 was a "turning point": the CIRP started in December 2023 and the NCLT approved the resolution plan on 7 February 2025. - The company has since started operations in the agro-commodities sector. It frames this as a strategic shift away from the legacy textile business towards a more diversified, growth-oriented model. PitchBook's profile, derived from filings, describes the current activity as trading of agro-commodities and commission business, alongside the legacy textile-trading objects. Screener's older profile says the company worked on a commission basis with cloth merchants, entirely within India. Simply Wall St also lists objects covering trading, wholesale, retail, distribution and export of precious and semi-precious metals, stones, gold, silver, diamonds, gems, jewellery and bullion. These are permitted objects in the Memorandum. No revenue from them is disclosed. On 22 May 2026 the company told BSE that it had altered the Object Clause of its Memorandum of Association. This followed board approval (27-Feb-2026) to add comprehensive agricultural and FMCG operations to its objects (Foliopulse filing history; ScanX board-outcome summary). ### Independent characterisation | Dimension | Assessment | |---|---| | Business model | Asset-light trading intermediary. The company buys and resells agro commodities and/or earns commission. There is no evidence of owned manufacturing, processing or brands at the listed-entity level as of Q1 FY2027 | | Revenue model | 100% product trading and commission. No subscription, licensing or service income disclosed | | Value-chain position | Mid-stream trader and distributor between growers/processors and dealers. The withdrawn food acquisitions (Section 11) would have added basmati rice, pulses and agro-products distribution through dealer networks in Gujarat | | Customer types | Not publicly disclosed. Likely B2B traders and distributors in Gujarat, given promoter geography and the nature of the targets | | End-markets | Indian domestic agro-commodities (grains, pulses, oilseeds, rice) and, historically, textiles. Geography is entirely India | | Scale | FY2026 revenue ₹2.51 Cr, all booked in Q4 FY2026. Q1 FY2027 revenue ₹0.99 Cr at a 4.04% operating margin (Business Standard / Capital Market, 18-Jul-2026) | | Operating reality | About 4 employees (Simply Wall St). Board-led, promoter-funded. Ongoing auditor disclaimers. The business is in a "re-start" phase rather than steady state |

Revenue$0.0B
Employees4
Market Cap$0.0B
Founded1993
Mira, India
Aligned

Aligned Genetics, Inc.

Premium
Information Technology

Aligned Genetics is a small, export-oriented Korean life-science instrumentation company that grew out of Logos Biosystems, a 2008 start-up best known for its LUNA™ family of automated cell counters. It sells under two brands. Logos Biosystems (tagline "Better Tools for Better Science") covers research tools: image-based automated cell counters, bacterial counters, digital and high-content cell imaging systems, and X-CLARITY™ tissue-clearing systems licensed from Stanford's CLARITY technology. Genescale ("Faster Answers for Faster Care") is its molecular-diagnostics brand, aimed at rapid diagnosis at the point of care. The company earns roughly half its revenue from instruments and half from proprietary consumables, which gives it a razor-and-blade recurring stream. Exports account for the large majority of sales; it has US, French and Japanese affiliates and OEM/ODM relationships, including a historical ODM supply arrangement with Olympus and a 2025 OEM contract in China. It is profitable, but growth has slowed sharply since 2023. --- ### What the company does Aligned Genetics designs, manufactures and sells laboratory instruments and associated consumables for life-science research and bioprocessing, and is building a molecular-diagnostics (MDx) business for clinical use. Its core competence is compact, image-based optical analysis: brightfield and fluorescence imaging, autofocus, and image-analysis software. It applies this to counting and characterising cells (mammalian cells, stem cells, yeast and bacteria), imaging cells in culture, and clearing and imaging whole tissue samples. ### The company's own description The company describes itself on its website as developing innovative technologies and products to open the future of life sciences and molecular diagnostics. It says it is growing two core brands, one for life-science solutions and one for molecular-diagnostic solutions (company website, "Our Brands"). S&P Global's profile, via Simply Wall St, describes the company as offering cellular imaging and biomolecular analysis solutions worldwide, with molecular diagnostics under the Genescale name and imaging and analysis solutions under the Logos Biosystems name. ### Independent characterisation In practice, Aligned Genetics today is overwhelmingly a cell-counter company. The LUNA franchise (LUNA, LUNA-FL, LUNA-II, LUNA-STEM, LUNA-II YF, LUNA-FX7, LUNA-III, LUNA-BX7) and its proprietary counting slides and reagents appear to make up most revenue. That is an inference from the product catalogue, the 50/49 instrument/consumable split, the awards record and the 2025 China OEM deal, all of which centre on cell counters. The company does not publish revenue by product family. The adjacent businesses are smaller: **Imaging:** CELENA® S digital imaging and CELENA® X high-content imaging. **Tissue clearing:** X-CLARITY™, a niche neuroscience tool. **Microbial counting:** QUANTOM™ / QUANTOM Tx™, notably for microbiome drug manufacturing under GMP. **Emerging projects:** SpectraSlide® (2025) and CosmoSort™ cell sorting (a 2024 manufacturing-supply agreement with Meteo Biotech). The Genescale MDx business has a GMP manufacturing facility (Hanam, 2023) and a Korean MFDS medical-device certification for a molecular-diagnostic instrument (reported September 2026). However, it has not yet produced disclosed, material revenue. ### Business and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Product vs. service mix | Instruments about 50%, consumables about 49%, other about 1% (Q2 2026 revenue basis) | Butler (DART-derived segment data) | | Subscription / licensing | No subscription model disclosed. Historically earned technology fees from ODM contracts (2014 and 2015 ODM agreements with a "global top-tier optical systems company" included technology fees). | Company history | | Channel | Own brand sold through about 50 distributors in 41 countries (2016) plus direct subsidiaries in the US (2012), France (2016) and Japan (2025); ODM/OEM supply to global and Chinese partners | Sidae (2016); company history | | Value-chain position | Original equipment manufacturer and brand owner; designs optics, hardware, software and consumables in-house; ODM/OEM supplier to larger instrument brands | Company history; Sidae (2016) | | Customer types | Academic and government research labs, biopharma R&D, cell and gene therapy and bioprocess developers, microbiome therapeutics manufacturers (QUANTOM Tx under GMP), OEM partners; prospectively hospitals and point-of-care clinical sites (Genescale) | Company history; brand pages | | End-markets | Life-science research tools (cell counting and analysis, cell imaging, neuroscience tissue clearing), bioprocessing QC, in-vitro diagnostics (molecular) | Company website | | Geographic orientation | Export-heavy: 97.9% export share in H1 2016 (Sidae); about 86% export in trailing-twelve-month data to Q3 2025 (ValueLine Korea) | See Section 7 |

Revenue$0.0B
Employees67
Market CapN/A
Founded2008
Gunpo, South Korea
Alicon

Alicon Castalloy Limited

Premium
Information Technology

Alicon Castalloy is one of India's largest integrated aluminium-castings manufacturers and a recognised pioneer of low-pressure die casting (LPDC) and gravity die casting (GDC) in the country. It operates four plants — Shikrapur and Chinchwad (Pune), Binola (Haryana) and Slovakia — supported by tool rooms, a technology centre, validation labs and machine shops, and offers end-to-end services from simulation and tooling through casting, machining, painting and sub-assembly. Roughly 96% of revenue is automotive, spanning two-wheelers, passenger vehicles and commercial vehicles, with a growing presence in EV/hybrid structural parts (e-axle, motor and battery housings) and nascent non-automotive niches such as data-centre precision components. The company combines a Japanese quality heritage (Enkei), a European engineering arm (Illichmann Castalloy) and Indian cost-competitiveness. FY2026 total income was INR 1,784 Cr; the executable order book stands at roughly INR 8,000–8,450 Cr through FY2031. Its key challenge is converting volume growth into higher return on capital. --- ### What the company does Alicon designs, engineers and manufactures aluminium alloy castings — predominantly safety- and performance-critical powertrain, structural and housing components — for automotive OEMs and Tier-1 suppliers, with a smaller non-automotive book. Its own investor materials describe it as offering end-to-end solutions across the full spectrum of aluminium casting needs, being a pioneer in India for LPDC and GDC, operating one of the country's largest aluminium foundries, and being a leader in casting-simulation software (Pro-Cast, Magma) usage in India (Q1 FY27 investor presentation, 13-Aug-2026). The integrated service chain disclosed by the company comprises: prototype design and manufacturing; tool design and simulation; tool manufacturing (in-house tool rooms with a stated capacity of about 20 tools per month); fixture design and manufacturing; casting manufacturing; value-analysis/value-engineering (VA/VE) suggestions; machining and sub-assembly; and painting/surface treatment (Q1 FY27 presentation). ### Company's own description (paraphrased from latest disclosures) In its FY26/Q1 FY27 communications, Alicon positions itself as one of India's largest integrated aluminium-casting manufacturers serving automotive, infrastructure, aerospace, energy, agriculture, defence and healthcare, with facilities at Shikrapur, Chinchwad and Binola in India and in Slovakia. It describes its proposition as a blend of European engineering, Japanese quality and Indian frugality, drawing on the cumulative experience of the Alicon group companies (Alicon, Atlas Castalloy, Enkei Corporation and Illichmann Castalloy — "235+ years of cumulative experience" in the company's framing). Management under the new CEO (from 1-Apr-2026) has stressed that customers increasingly view Alicon as a long-term engineering and manufacturing partner rather than a component vendor (Q4 FY26 earnings call, May-2026). ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue model | ~100% product sales (build-to-print / co-developed castings and machined assemblies). Tooling and development income is incidental and not separately disclosed. No subscription, licensing or service revenue of significance | | Contract structure | Multi-year, part-number-specific supply nominations ("programmes") awarded at RFQ stage; lifetime values booked into an executable order book with anticipated production schedules over six years | | Pricing | Aluminium alloy cost is largely passed through to customers via index-linked formulae, with a time lag. Management indicated a transition toward back-to-back (concurrent) pricing on some contracts (Q1 FY27 commentary). Conversion (value-add) pricing is negotiated and subject to annual price-downs typical of the auto sector | | Value-chain position | Tier-1/Tier-2 component supplier; buys primary/secondary aluminium alloy ingots, adds metallurgy, casting, heat-treatment, machining and assembly value; supplies OEMs (Hero MotoCorp, Bajaj Auto, Maruti Suzuki, Mahindra, Daimler India CV, Ashok Leyland, Toyota Industries Engine India, Honda two-wheelers, JLR) and Tier-1s (e.g., MAHLE, Danfoss, Garrett, Knorr-Bremse, ZF historically) | | Customer types | 2W/3W OEMs; 4W (PV and CV) OEMs; Tier-1 system suppliers; non-auto industrial OEMs | | Customer count | 92 customers with 809 live parts (Q1 FY27 presentation) | | Concentration | CRISIL (Aug-2026) notes no single customer contributes a significant share, though the two-wheeler segment remains a significant revenue contributor | | Mix (Q1 FY27) | Auto 96% / Non-auto 4%; Domestic 88% / Global 12% | | Mix (FY26) | Exports ~20% of revenue (CRISIL, Aug-2026) | ### End-markets served Automotive: two- and three-wheelers (cylinder heads, crankcase-related and engine castings), passenger vehicles (cylinder heads, intake manifolds, brackets, EV/hybrid housings incl. e-axle housings), commercial vehicles (heavy-truck engine parts, cooling-module housings, turbo components). Non-automotive: infrastructure, defence, medical, energy, agriculture, aerospace and "carbon-neutral" technologies; most recently, precision components for data-centre infrastructure (FY26 Annual Report summary, Sep-2026). ### Independent characterisation Alicon is a mid-sized, promoter-controlled, capital-intensive foundry business with genuine technical depth in gravity and low-pressure aluminium casting — processes suited to high-integrity parts such as cylinder heads and structural housings. Its strategic narrative over FY2019–FY2024 was a mix-shift from two-wheeler engine parts toward PV, CV, exports and EV/hybrid structural parts. That shift largely succeeded in the order book (where 4W dominated as early as FY2023) but has been slow to translate into revenue and margins because several high-value export and EV programmes (notably the JLR e-axle) were delayed, US CV demand weakened, and European demand was subdued. The result has been revenue growth with stagnant profit: FY2026 net profit of INR 34 Cr is well below the FY2024 peak of INR 61 Cr. The business has robust operating cash generation (CFO/EBITDA above 100% in FY25–FY26) but structurally thin net margins (~2%) owing to heavy depreciation from continual capex and moderate leverage. The 2026 CEO transition, a new INR 125 Cr plant and a domestic-led revenue surge in Q1 FY27 mark an inflection attempt.

Revenue$0.2B
Employees941
Market CapN/A
Founded1990
District Pune, India

Page 88 of 482

1…878889…482

Page 88 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo